



Department of Health  
Pharmaceutical Division



# Philippine National Formulary



8<sup>th</sup> Edition

**ESSENTIAL MEDICINES LIST**





# **Philippine National Formulary**

## **Essential Medicines List (as of November 02, 2022)**

*For new updates, you may download the latest version (PDF copy) at  
[www.pharmadiv.gov.ph](http://www.pharmadiv.gov.ph)*

## **Volume I, 8<sup>th</sup> Edition (2019)**

*Published by:*

**Pharmaceutical Division – Health Regulation Team  
DEPARTMENT OF HEALTH  
Manila, Philippines**



**PHILIPPINE NATIONAL FORMULARY  
ESSENTIAL MEDICINES LIST**

**8<sup>th</sup> Edition**

**2017**

**DEPARTMENT OF HEALTH**

**Francisco T. Duque III, MD, MSc**  
*Secretary of Health*

**Rolando Enrique D. Domingo, MD, DPBO**  
*Undersecretary of Health*  
*Health Regulation Team*

**Lyndon L. Lee Suy, MD, MPH**  
*Assistant Secretary of Health*  
*Health Regulation Team*

**FORMULARY EXECUTIVE COUNCIL**

**Froilan A. Bagabaldo, RPh, LIB** (*Chair*)

**Cleotilde H. How, MD, FPSECP, FPPS**

**Cecilia A. Jimeno, MD, FPCP, FPSEDM**

**Cecilia C. Maramba-Lazarte, MD, MScID, MSCCT, FPPS, FPIDSP, FPSECP**

**Paul Matthew D. Pasco, MD, MSc, FPNA**

**Imelda G. Peña, RPh, MS, DrPH**

**John Q. Wong, MD, MSc**



**PHILIPPINE NATIONAL FORMULARY  
ESSENTIAL MEDICINES LIST**

**8<sup>th</sup> Edition**

**2017**

**PHILIPPINE NATIONAL FORMULARY SECRETARIAT**

**Anna Melissa S. Guerrero, MD, MPH, (HTA)**

*Chief*

*Pharmaceutical Division*

**Irene V. Florentino-Fariñas, RPh, MD, MNSA**

*Medical Officer IV*

*Pharmaceutical Division*

**Joyce Anne dP. Ceria-Pereña, RPh, MPM**

*Pharmacist V*

**Johanna B. Mallari, RPh**

*Pharmacist III*

**Anna Patricia D. Tiosejo, RPh**

*Pharmacist II*

**John Michael L. Roque**

*Technical Assistant*



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

**MESSAGE**

The revitalization of the Fourmula One Plus for Health as the framework of the healthcare reform agenda of the national government is anchored on the values of equitable and inclusive health system, transparent and accountable provision of quality health services, and efficient use of resources. The 8<sup>th</sup> edition of the Philippine National Formulary (PNF) Essential Medicines List (EML) is a tool to exercise these values while contributing to the achievement of the objectives of financial protection and better health outcomes.

As an essential medicines list, its previous editions have been the basis of tailored procurement of medicines in public health facilities while providing efficient use of limited resources. It is also the basis of the Philippine Health Insurance Corporation (PhilHealth) in reimbursing claims to end-users for medicines use.

With its new format and content, the PNF EML 8<sup>th</sup> edition can now maximize the PNF's contribution to the rational use of medicines. Its abridged content is intended to provide concise evidence-based drug information which is vital in medical practice.

The latest PNF EML is a useful tool to ensure rational prescribing, dispensing and administration of medicines. I would like to encourage our health professionals to fully utilize it in their medicines procurement as well as in their day-to-day clinical decision-making.

Let us continue to work for our shared vision of all for health towards health for all!

*Mabuhay!*



FRANCISCO T. DUQUE III, MD, MSc  
Secretary of Health



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

21 July 2016

**DEPARTMENT MEMORANDUM**

No.2016- 0258

**FOR:** ALL DIRECTORS OF BUREAUS AND REGIONAL OFFICES, SECRETARY OF HEALTH DOH-ARMM; CHIEFS OF MEDICAL CENTERS, HOSPITALS AND SANITARIA; AND OTHERS CONCERNED

**SUBJECT:** Further clarification and guidance on the bidding specifications of solid oral dosage forms (tablets) in the Philippine National Formulary (PNF)

---

This is to inform everyone that, as per clarification and recommendation of the Food and Drug Administration (FDA), the bidding of TABLET shall be open to both uncoated and coated (film- and sugar-coated) tablets, unless otherwise specified in the PNF.

On the other hand, for the bidding of the following solid oral dosage forms, the specific type of tablet should be clearly reflected in the purchase request:

1. film-coated tablets;
2. soluble tablets;
3. dispersible tablets;
4. effervescent tablets;
5. chewable tablets;
6. tablets for use in the mouth (including orally disintegrating, sublingual and buccal tablets); and
7. modified-release tablets (including delayed-release tablets gastro-resistant/enteric-coated tablets) and sustained-release tablets (extended-/prolonged-release tablets)).

For urgent and strict implementation.

  
PAULYN JEAN B. ROSELL-UBIAL, MD, MPH, CESO II  
Secretary of Health



## ABBREVIATIONS AND SYSTEM OF MEASUREMENTS

|        |   |  |
|--------|---|--|
| ●      | - | Medicinal plant product registered with BFAD   |
| +      | - | Use with extreme caution in doses exceeding 30 mg per day; contraindicated in acute coronary events  |
| (1)    | - | Specific expertise, diagnostic precision, or special equipment required for proper use   |
| (2)    | - | Limited indications or narrow spectrum of activity   |
| (A1)   | - | Dangerous Drug Preparations to be prescribed and dispensed through the DOH Official Prescription Form (Yellow Rx). Only one (1) dangerous drug preparation shall be prescribed in one single prescription form. Partial filling allowed. STRICTLY NO REFILL.   |
| ⊗      | - | To be prescribed using Personalized Prescription issued by the prescribing physician with the S2 license # indicated therein. Only one (1) drug preparation shall be prescribed in one single prescription form. Partial filling allowed. STRICTLY NO REFILL.  |
| (A2)   | - | Drug Preparations Containing Controlled Chemicals to be dispensed and prescribed through a Personalized Prescription issued by a prescribing physician with the S2 license #, among others, indicated therein. Only one (1) drug preparation shall be prescribed in one single prescription form. Partial filling allowed. STRICTLY NO REFILL. |
| B      | - | List B medicines requiring <i>in vivo</i> bioequivalence studies   |
| DPI    | - | Dry Powder Inhaler   |
| equiv. | - | equivalent   |
| EU     | - | ELISA Unit   |
| g      | - | Gram   |
| (ID)   | - | Intradermal Injection  |
| (IM)   | - | Intramuscular Injection  |
| Inj.   | - | Injection  |
| IU     | - | International Unit/s   |
| (IV)   | - | Intravenous Injection  |
| L      | - | Liter  |
| mcg    | - | Microgram  |
| mCi    | - | Millicurie   |

|                |   |   |
|----------------|---|---|
| MDI            | - | Metered Dose Inhaler  |
| mEq            | - | Milliequivalent   |
| mg             | - | Milligram   |
| mL             | - | Milliliter  |
| MR             | - | Modified Release (includes Controlled Release (CR),<br>Extended Release (ER) Sustained Release (SR),<br>Long Acting (LA), etc.)               |
| NSAID          | - | Non-Steroidal Anti-Inflammatory Drug  |
| pen. G         | - | Penicillin G  |
| PFU            | - | Plaque Forming Unit   |
| RE             | - | Retinol Equivalent  |
| Resp.<br>Soln. | - | Respiratory Solution  |
| S2             | - | License required for prescription of Dangerous<br>Drugs Preparations and Controlled Chemicals by the<br>Physicians / Dentists / Veterinarians |
| (SC)           | - | Subcutaneous Injection  |
| Soln.          | - | Solution  |

#### MEASUREMENTS:

1 grain = 60 mg

½ grain = 30 mg

Quantities of 1 gram or more should be written as 1 g, etc.

Quantities of less than 1 gram should be written in milligrams, e.g., 500 mg,  
not 0.5 g.

Quantities less than 1 milligram should be written in microgram/s, e.g., 100  
microgram/s not 0.1 mg.

When decimals are unavoidable, a zero should be written before the decimal  
point where there is no figure, e.g., 0.5 mL, not .5 mL.

The term milliliter (mL) should be used and not cubic centimeters or cc or  
m<sup>3</sup>.

| Active Ingredient                          | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| <b>A</b>                                   |  |
| Abacavir                                   | Oral: 300mg tablet (as sulfate)  |
| Acetated Ringer's Solution                 | Inj.: 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Na+ — 130 mmol/L<br>K+ — 4 mmol/L<br>Ca++ — 3 mmol/L<br>Cl- — 109 mmol/L  |
| Acetazolamide (B)                          | Oral: 250 mg tablet  |
| Acetylcysteine                             | Oral: 600 mg effervescent tablet<br>100 mg and 200 mg sachet<br>100 mg/5 mL granules for suspension, 150 mL<br>Inj.: 200 mg/mL, 10 mL ampul (IV infusion) (1, 2)<br>200 mg/mL, 25 mL bottle (IV infusion)<br>Inhalation:<br>100 mg/mL, 3 mL ampule solution for inhalation |
| Aciclovir                                  | Oral: 200 mg, 400 mg and 800 mg tablet<br>200 mg/5 mL suspension, 60 mL and 120mL<br>Inj.: 25 mg/mL, 10 mL vial (IV infusion)  |
| Activated Charcoal                         | Oral: powder, USP grade given as slurry  |
| Adenosine (1, 2)                           | Inj.: 3 mg/mL, 2 mL vial (IV)  |
| Adrenaline (see Epinephrine)               |  |
| Albendazole                                | Oral: 400 mg chewable tablet (B)<br>200 mg/5 mL suspension, 10 mL and 60 mL  |
| Albumin, Human (1, 2)                      | Inj.: 20%, 50 mL and 100 mL bottle (IV, IV infusion)<br>25%, 50 mL and 100 mL bottle (IV, IV infusion)<br>25%, 50 mL plastic bag (IV, IV infusion)   |
| Alcohol, Ethyl (1, 2)                      | Oral: 95%, USP grade<br>Inj.: absolute, 1 mL ampul (IV)<br>Solution:<br>70% topical solution   |
| Alendronate (as sodium salt)               | Oral: 10 mg and 70 mg tablet   |
| Alendronate + Cholecalciferol (vitamin D3) | Oral: 70 mg (as sodium salt) + 5600 IU tablet  |
| Alfuzosin (as hydrochloride)               | Oral: 10 mg tablet   |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| All-in-one Admixtures  | Solution:<br>Volume: 400 – 2500 mL<br>Concentration:<br>Variable<br>Protein:<br>3–6 g/100 mL<br>Carbohydrate:<br>6–15 g/100 mL Lipid: 2–5 g/ 100mL<br>Calories:<br>variable<br>Electrolytes:<br>variable |
| Allopurinol  | Oral: 100 mg and 300 mg tablet   |
| Alprazolam (A1)  | Oral: ⊗250 microgram, 500 microgram and 1 mg tablet  |
| Aluminum Hydroxide + Magnesium Hydroxide                     | Oral: 225 mg aluminum hydroxide + 200 mg magnesium hydroxide per 5 mL suspension, 60 mL and 120 mL<br><br>200 mg aluminum hydroxide + 100 mg magnesium hydroxide tablet                                  |
| Amikacin (as sulfate)  | Inj.: 50 mg/mL, 100 mg/mL, 125 mg/mL and 250 mg/mL, 2 mL ampul/vial (IM, IV)<br>100 mg, 250 mg, 500 mg and 1 g vial (IM, IV)   |
| Amino Acid + carbohydrate + multivitamins + electrolytes     | Inj.: solution for IV injection/infusion set, 1000 mL  |
| Amino Acid + glucose + electrolytes + vitamin B1             | Inj.: solution for peripheral venous infusion 500 mL and 1000 mL   |
| Amino Acid Solutions for Immunonutrition / Immunoenhancement | Solution:<br>Volume - 50 mL and 100 mL<br>Protein - 20 g; L-alanyl-L- glutamine<br>Calories - 70 - 90<br>Electrolytes - none   |
| Amino Acid Solutions for Infants                             | Solution:<br>Volume - 100 mL<br>Concentration - 5 - 10 %<br>Protein - 5 - 10 g including taurine<br>Calories - 20 - 40 kcal<br>Electrolytes - none   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| Amino Acid Solutions for Renal Condition  | Solution:<br>Volume - 250 - 500 mL<br>Concentration - 3.5 - 7 %<br>Protein - 17.5 - 35 g rich in essential amino acid<br>Calories - 50 - 200 Kcal  |
| Amino Acid Solutions for Hepatic Failure  | Solution:<br>Volume - 500 mL Concentration - 5 - 10 %<br>Protein - 35-50 g; rich in branched-chain amino acids<br>Calories - 50 - 200<br>Electrolytes - variable   |
| Amino Acids, Crystalline Standard   | Inj.: 3.5%, 500 mL bottle (IV infusion)<br>5%, 100 mL, 250 mL and 500 mL bottle (IV infusion)<br>6%, 100 mL and 250 mL bottle (IV infusion)<br>7%, 8.5%, 10%, and 11.4%, 100 mL, 500 mL and 1 L bottle (IV infusion)<br>8%, 500 mL bottle (IV infusion) (as branched chain)<br>9.12%, 20 mL ampul and 200 mL bottle (IV infusion)<br>10%, 100 mL and 500 mL bottle (IV infusion) |
| Aminophylline (theophylline ethylenediamine) (1)  | Inj.: 25 mg/mL, 10 mL ampul (IV)   |
| Amiodarone (as hydrochloride) (2)   | Oral: 200 mg tablet<br>Inj.: 50 mg/mL, 3 mL ampul (IV) (2)   |
| Amlodipine (as besilate/camsylate)  | Oral: 5 mg and 10 mg tablet  |
| Amoxicillin (as trihydrate)   | Oral: 250 mg and 500 mg capsule<br>100 mg/mL granules/powder for drops (suspension), 15 mL<br>250 mg/5 mL granules/powder for suspension, 60 mL  |
| Amoxicillin + Potassium Clavulanate (see Co-Amoxiclav)  |  |
| Amphotericin B (Lipid Complex) (as cholesteryl complex, colloidal dispersion) (1) <b>*Reserve Antimicrobial</b> | Inj.: 50 mg and 100 mg vial (IV infusion)  |
| Amphotericin B (Non-Lipid Complex) (1) <b>*Reserve Antimicrobial</b>  | Inj.: 50 mg lyophilized powder, vial (IV infusion)   |
| Ampicillin (as sodium salt)   | Inj.: 250 mg, 500 mg and 1 g vial (IM, IV)   |

| Active Ingredient                                   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
| Ampicillin + Sulbactam                              | Inj.: 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial<br>1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial<br>2000 mg ampicillin + 1000 mg sulbactam (IM, IV) (as sodium salt) per vial      |
| Anastrozole   | Oral: 1 mg film coated tablet   |
| Anti-D Immunoglobulin (human anti-D immunoglobulin) | Inj.: 200 micrograms/mL, 1.5 mL ampul (IM)  |
| Antilymphocyte Immunoglobulin (ALG) (equine) (1, 2) | Inj.: 100 mg/5 mL vial (IV)   |
| Anti-thymocyte Immunoglobulin (ATG) (rabbit) (1, 2) | Inj.: 25 mg/5 mL vial (IV)  |
| Anti-rabies serum (equine)                          | Inj.: 200 IU/mL, 5 mL vial (IM)<br>400 IU/mL, 5 mL vial (IM)  |
| Anti-tetanus serum (equine)                         | Inj.: 4000 IU/mL, 2.5 mL vial (IM)<br>1500 IU/0.7 mL solution for injection, vial/ampul (IM)<br>1500 IU/mL, 1 mL and 1.5 mL vial/ampul (IM)   |
| Aripiprazole  | Oral: 10 mg, 15 mg, 20 mg and 30 mg tablet<br>10 mg and 15 mg orally disintegrating tablet (ODT)<br>Inj.: 300 mg and 400 mg (200 mg/mL) lyophilized powder for extended-release suspension for injection in pre-filled dual chamber syringe |
| Artemether + Lumefantrin (B)                        | Oral: 20 mg artemether + 120 mg lumefantrin tablet  |
| Artesunate  | Inj.: 60 mg vial injectable<br>Rectal: 50 mg suppository  |
| Ascorbic Acid (vitamin C)                           | Oral: 100 mg and 500 mg tablet<br>100 mg/5 mL syrup, 60 mL and 120 mL<br>100 mg/mL drops, 15 mL and 30 mL<br>Inj.: 250 mg/mL, 2 mL ampul (IV) (1, 2)  |
| Asparaginase (1, 2)                                 | Inj.: lyophilized powder, 10,000 IU vial (IV)   |
| Aspirin   | Oral: 80 mg, 100 mg tablet, 300 mg tablet and 325mg tablet  |
| Atenolol  | Oral: 50 mg and 100 mg tablet   |
| Atorvastatin calcium                                | Oral: 10 mg, 20 mg, 40 mg and 80 mg tablet  |
| Atracurium (as besilate)                            | Inj.: 10 mg/mL, 2.5 mL and 5 mL ampul (IV)  |
| Atropine (as sulfate) (1, 2)                        | Oral: 600 micrograms (equiv. to 500 mcg atropine) tablet<br>Inj.: 500 micrograms/mL, 600 micrograms/mL and 1 mg/mL, 1 mL ampul (IM, IV, SC) Eye Drops<br>Solution:  |

| Active Ingredient                                | Route of Administration<br>Pharmaceutical Forms and Strengths  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
|--|--|-------------------|---------|-------------------|----------|--------|--------|-----------------|--------------|--------------|----------------|--------------|--------------|------------------|------------------|-------------|-----------------|-----------|-----------|---------|-----------|-----------|
|  | 1%, 5 mL and 10 mL bottle  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Azathioprine (1, 2) (B)                          | Oral: 50 mg tablet   |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Azithromycin                                     | Oral: 250 mg capsule (as base*/as dihydrate)<br>250 mg and 500 mg (B) tablet (as base*/as dihydrate/as monohydrate)<br>200 mg/5 mL powder for suspension, 15 mL and 60 mL (as base*/as dihydrate/as monohydrate)<br>Inj.: 500 mg powder, vial (IV infusion) (as base*/as dihydrate)  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Aztreonam<br><b>*Reserve Antimicrobial</b>       | Inj.: 1 g powder for injection   |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| <b>B</b>   |  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Bacitracin + Neomycin + Polymyxin B              | Ointment:<br>200 units bacitracin + 3 mg neomycin (as sulfate) + 4000 units polymyxin B (as sulfate)/g, 10 g tube  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Baclofen   | Oral: 10 mg tablet   |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Balanced Multiple Maintenance Solution           | Inj.: with 5% dextrose, 250 mL and 500 mL (infants) and 1 L (children and adults) bottle/bag (IV infusion)<br><br>Composition:<br><table border="1" data-bbox="442 914 1050 1114"> <thead> <tr> <th></th> <th>Infants</th> <th>Children &amp; Adults</th> </tr> </thead> <tbody> <tr> <td>Dextrose</td> <td>50 g/L</td> <td>50 g/L</td> </tr> <tr> <td>Na<sup>+</sup></td> <td>25-30 mmol/L</td> <td>40-50 mmol/L</td> </tr> <tr> <td>K<sup>+</sup></td> <td>20-25 mmol/L</td> <td>13-30 mmol/L</td> </tr> <tr> <td>Mg<sup>++</sup></td> <td>1.35-1.65 mmol/L</td> <td>1.65 mmol/L</td> </tr> <tr> <td>Cl<sup>-</sup></td> <td>22 mmol/L</td> <td>40 mmol/L</td> </tr> <tr> <td>Acetate</td> <td>23 mmol/L</td> <td>16 mmol/L</td> </tr> </tbody> </table> |                   | Infants | Children & Adults | Dextrose | 50 g/L | 50 g/L | Na <sup>+</sup> | 25-30 mmol/L | 40-50 mmol/L | K <sup>+</sup> | 20-25 mmol/L | 13-30 mmol/L | Mg <sup>++</sup> | 1.35-1.65 mmol/L | 1.65 mmol/L | Cl <sup>-</sup> | 22 mmol/L | 40 mmol/L | Acetate | 23 mmol/L | 16 mmol/L |
|  | Infants  | Children & Adults |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Dextrose   | 50 g/L   | 50 g/L            |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Na <sup>+</sup>                                  | 25-30 mmol/L   | 40-50 mmol/L      |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| K <sup>+</sup>                                   | 20-25 mmol/L   | 13-30 mmol/L      |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Mg <sup>++</sup>                                 | 1.35-1.65 mmol/L   | 1.65 mmol/L       |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Cl <sup>-</sup>                                  | 22 mmol/L  | 40 mmol/L         |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Acetate  | 23 mmol/L  | 16 mmol/L         |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Balanced Multiple Replacement Solution           | Inj.: 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Na <sup>+</sup> — 140-145 mmol/L<br>K <sup>+</sup> — 4-5 mmol/L<br>Mg <sup>++</sup> — 1-1.65 mmol/L<br>Cl <sup>-</sup> — 98-127 mmol/L<br>Acetate — 24-50 mmol/L<br>plus 5% dextrose (50g/L)  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |
| Balanced Multiple Replacement Solution w/ pH 7.4 | Inj.: 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Na <sup>+</sup> — 140 mmol/L  |                   |         |                   |          |        |        |                 |              |              |                |              |              |                  |                  |             |                 |           |           |         |           |           |

| Active Ingredient                                       | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | K+ — 5 mmol/L<br>Mg++ — 3 mmol/L<br>Cl- — 98 mmol/L<br>Acetate — 50 mmol/L  |
| Barium Sulfate  | Oral: powder, USP grade suspended in water 340 g and 454 g, pouch, LDPE bag   |
| Basiliximab (1, 2)                                      | Inj.: 20 mg vial (IV infusion)  |
| BCG Vaccine   | Inj.: freeze-dried powder, 100 micrograms/0.1 mL, 1 mL, 1.5 mL and 2 mL vial (ID)<br>500 micrograms/mL vial + 1 mL diluent in ampul (ID) 20 doses   |
| Bedaquiline fumarate                                    | Oral: 100 mg tablet (For use by the National Tuberculosis Control Program (NTP) of the Department of Health (DOH) only.)  |
| Benzoyl Peroxide  | Gel: 5%, 20 g tube  |
| Benzyl Benzoate   | Lotion: 25%, 60 mL and 120 mL bottle  |
| Beractant   | Inj.: 25 mg/mL suspension, 4 mL and 8 mL vial, Intratracheal administration (restricted to tertiary hospitals with adequately trained neonatologist and facilities for neonatal intensive care) |
| Betahistine (as hydrochloride/dihydrochloride)          | Oral: 8 mg, 16 mg and 24 mg tablet  |
| Betamethasone   | Cream or Ointment:<br>0.05%, 5 g and 10 g tube (as dipropionate)<br>0.1%, 5 g tube (as valerate)  |
| Betaxolol (as hydrochloride)                            | Eye Drops Suspension:<br>0.25%, 5 mL bottle Eye Drops Solution:<br>0.5%, 5 mL and 10 mL bottle  |
| Bicalutamide  | Oral: 50 mg and 150 mg tablet/ film coated tablet   |
| Biperiden   | Oral: 2 mg tablet (as hydrochloride)<br>Inj.: 5 mg/mL, 1 mL ampul (IM, IV) (as lactate)   |
| Biphasic Isothane Human Insulin 70/30 (recombinant DNA) | Inj.: 70% isophane suspension + 30% soluble insulin in:<br>100 IU/mL, 5 mL and 10 mL vial (SC)<br>100 IU/mL, 3 mL disposable syringe (SC)<br>100 IU/mL, 3mL glass cartridge (SC)                |
| Bisacodyl   | Oral: 5 mg tablet<br>5 mg MR tablet<br>Rectal: 5 mg (children) and 10 mg (adult) suppository  |
| Bisoprolol  | Oral: 2.5 mg and 5 mg tablet (as fumarate)  |
| Bleomycin (as sulfate) (1, 2)                           | Inj.: powder, 15 IU ampul/vial (IM, IV)   |

| Active Ingredient                     | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---------------------------------------|---|
| Brimonidine (as tartrate)             | Ophthalmic Solution:<br>0.15%, 5 mL bottle  |
| Brinzolamide                          | Ophthalmic Suspension:<br>1%, 5 mL bottle   |
| Bromazepam (A1)                       | Oral: ⊗1.5 mg tablet  |
| Bromocriptine (as mesilate)<br>(1, 2) | Oral: 2.5 mg tablet   |
| Budesonide                            | Inhalation:<br>DPI: 100 micrograms/dose x 200 doses with appropriate accompanying dispenser<br>200 micrograms/dose x 100 doses and 200 doses with appropriate accompanying dispenser<br>MDI: 200 micrograms/dose x 120 actuations<br>Resp. Soln.: (for nebulization) 250 micrograms/mL, 2 mL (unit dose)  |
| Budesonide + Formoterol               | Inhalation:<br>DPI: 80 micrograms budesonide + 4.5 micrograms formoterol (as fumarate dihydrate) x 60 doses with appropriate accompanying dispenser<br>160 micrograms budesonide + 4.5 micrograms formoterol (as fumarate dihydrate) x 60 doses with appropriate accompanying dispenser<br>320 micrograms budesonide + 9 micrograms formoterol (as fumarate) x 60 doses with appropriate accompanying dispenser<br>MDI: 80 micrograms budesonide + 4.5 micrograms formoterol (as fumarate dihydrate) x 120 doses with appropriate accompanying dispenser<br>160 micrograms budesonide + 4.5 micrograms formoterol (as fumarate dihydrate) x 120 doses with appropriate accompanying dispenser |
| Bumetanide                            | Oral: 1 mg tablet<br>Inj.: 500 micrograms/mL, 4 mL ampul (IM, IV)   |
| Bupivacaine (as hydrochloride)<br>(1) | Inj.: 0.5%, 5 mL, 10 mL and 20 mL vial<br>0.5%, 5 mL, 10 mL, 20 mL and 50 mL ampul/vial (local infiltration)<br>0.5% 4 mL ampul (spinal) with 8% dextrose   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
|   | 0.5% (isobaric), 5 mL ampul (spinal)   |
| Butamirate (as citrate) (2)                                       | Oral: 50 mg MR tablet<br>7.5 mg/5 mL syrup, 120 mL   |
| Butorphanol (as tartrate) (A1)                                    | Inj.: 2 mg/mL, 1 mL and 2 mL ampul/vial (IM, IV)   |
| <b>C</b>  |  |
| Calamine, Plain   | Lotion: 8%, 60 mL and 120 mL bottle  |
| Calcipotriol  | Ointment:<br>50 microgram/g, 30 g tube or bottle   |
| Calcipotriol + Betamethasone                                      | Ointment:<br>50 microgram calcipotriol (as hydrate) + 500 microgram betamethasone (as dipropionate)/g, 30 g tube   |
| Calcitriol (1, 2)   | Oral: 0.25 microgram capsule   |
| Calcium   | Oral: tablet (equiv. to 500 mg elemental calcium) (as lactate)<br>tablet/chewable tablet (equiv. to 500 mg and 600 mg elemental calcium) (as carbonate) powder, USP grade (as chloride)<br>Inj.: 10% solution in 10 mL ampul (IV) (as gluconate) |
| Calcium Carbonate   | Oral: tablet/chewable tablet (equiv. to 500 mg and 600 mg elemental calcium)   |
| Calcium Carbonate + Cholecalciferol (vitamin D3)                  | Oral: Equiv. to 500 mg elemental Ca + 400 IU Vit. D3<br>Equiv. to 600 mg elemental Ca + 400 IU Vit. D3   |
| Calcium Folate (leucovorin calcium) (1, 2)                        | Inj.: 10 mg/mL, 5 mL ampul/vial (IM, IV) 50 mg vial (IM, IV)   |
| Calcium Gluconate (1, 2)  | Inj.: 10%, 10 mL ampul/vial (IV)<br>10%, 20 mL and 25 mL bottle (IV)   |
| Calcium Sennosides (equivalent to Standardized Senna concentrate) | Oral: 8.77 mg and 17.54 mg (calculated as sennoside B) tablet  |
| Capecitabine (1, 2)   | Oral: 150 mg and 500 mg tablet   |
| Capreomycin   | Inj.: 1 gram powder for injection (IV, IM)   |
| Captopril   | Oral: 25 mg and 50 mg tablet   |
| Carbachol   | Intraocular Solution:<br>0.01%, 1.5 mL vial  |
| Carbamazepine   | Oral: 200 mg tablet (B)<br>200 mg and 400 mg MR tablet 100 mg/5 mL syrup, 120 mL   |
| Carbetocin  | Inj.: 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)  |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| Carboplatin (1, 2)   | Inj.: powder, 150 mg and 450 mg vial (IV)<br>10 mg/mL, 15 mL and 45 mL vial (IV)   |
| Carboprost   | Inj.: 125 mcg/0.5 mL solution for injection, 0.5 mL<br>ampul/vial<br>250 mcg/mL solution for injection, 1 mL<br>ampule/vial  |
| Carboxymethylcellulose<br>(as sodium)                        | Eye Drops Solution:<br>0.5%, 0.4 mL and 15 mL bottle   |
| Carvedilol   | Oral: 6.25 mg tablet and 25 mg tablet  |
| Castor Oil   | Oral: USP grade  |
| Cefalexin (as monohydrate)                                   | Oral: 500 mg capsule<br>100 mg/mL, granules/powder for drops, 10 mL<br>125 mg/5 mL granules/powder for<br>syrup/suspension, 30 mL<br>250 mg/5 mL granules/powder for<br>syrup/suspension, 60 mL  |
| Cefazolin (as sodium salt)                                   | Inj.: 500 mg and 1 g vial (IM, IV)   |
| Cefepime (as hydrochloride)<br><b>*Reserve Antimicrobial</b> | Inj.: 500 mg, 1 g and 2 g vial (IM, IV)  |
| Cefixime   | Oral: 200 mg and 400 mg capsule (B)<br>20 mg/mL granules for drops (suspension), 10 mL<br>100 mg/5 mL granules for suspension, 60 mL   |
| Cefotaxime (as sodium salt)                                  | Inj.: 250 mg vial + 2 mL diluent (IM, IV) 500 mg vial + 2<br>mL diluent (IM, IV)   |
| Cefoxitin  | Inj.: 1 g vial (IM, IV) (as sodium salt)<br>1g (as sodium) powder for injection with 4%<br>Dextrose Solution for Injection (IV Infusion)   |
| Ceftaxidime (Ceftazidime)                                    | Inj.: 250 mg, 500 mg and 1 g vial (IM, IV) (as<br>pentahydrate)<br>2 g vial (IV infusion) (as pentahydrate)  |
| Ceftriaxone<br>(as disodium/sodium salt)                     | Inj.: 250 mg vial + 2 mL 1% solution of lidocaine (IM)<br>500 mg vial + 2 mL 1% solution of lidocaine (IM)<br>250 mg vial + 5 mL diluent (IV)<br>1 g vial + 3.5 mL 1% solution of lidocaine (IM)<br>1 g vial + 10 mL diluent (IV)                            |
| Cefuroxime   | Oral: 500 mg tablet (as axetil)<br>125 mg/5 mL granules for suspension, 70 mL (as<br>axetil)<br>250 mg/5 mL granules for suspension, 50 mL<br>content in 120 mL bottle<br>Inj.: 250 mg and 750 mg vial (IM, IV)<br>1.5 g vial (IV infusion) (as sodium salt) |

| Active Ingredient                                | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
| Celecoxib  | Oral: 100 mg, 200 mg and 400 mg capsule   |
| Cetirizine<br>(as dihydrochloride)               | Oral: 10 mg tablet<br>2.5 mg/mL syrup (oral drops), 10 mL<br>10 mg/mL drops, 10 mL<br>1 mg/mL solution, 30 mL and 60 mL<br>5 mg/5 mL syrup, 30 mL       |
| Chlorambucil (1, 2)                              | Oral: 2 mg tablet   |
| Chloramphenicol                                  | Oral: 500 mg capsule<br>125 mg/5 mL suspension, 60 mL (as palmitate)<br>Inj.: 1 g vial (IV; IM if recommended by manufacturer)<br>(as sodium succinate) |
| Chlorhexidine                                    | Solution:<br>0.12% and 4%, 50 mL, 120 mL, 380 mL, 500 mL,<br>4 L and 5 L (as gluconate)   |
| Chloroquine (as phosphate or diphosphate)        | Oral: 250 mg (150 mg base) tablet<br>Inj.: 50 mg/mL, 20 mL vial (IM, IV)  |
| Chlorphenamine<br>(Chlopheniramine) (as maleate) | Oral: 4 mg tablet<br>2.5 mg/5 mL syrup, 60 mL<br>Inj.: 10 mg/mL, 1 mL ampul/vial (IM, IV)   |
| Chlorpheniramine (see Chlorphenamine)            |   |
| Chlorpromazine (as hydrochloride)                | Oral: 100 mg and 200 mg tablet  |
| Ciclosporin (1, 2)                               | Oral: 25 mg, 50 mg and 100 mg capsule (B)<br>100 mg/mL solution, 50 mL<br>Ophthalmic Emulsion:<br>0.05%, 0.4 mL bottle                                  |
| Cilostazol                                       | Oral: 50 mg and 100 mg tablet<br>50 mg (20% w/w), 0.25 g sachet powder for oral use<br>100 mg (20% w/w), 0.5 g sachet powder for oral use               |
| Cinnarizine                                      | Oral: 25 mg tablet  |
| Ciprofloxacin                                    | Oral: 250 mg and 500 mg tablet (as hydrochloride)<br>Inj.: 2 mg/mL, 100 mL vial (IV infusion) (as lactate)<br>400 mg/200 mL (IV infusion)               |
| Cisplatin (1, 2)                                 | Inj.: 1 mg/mL, 10 mL and 50 mL vial (IV)  |
| Clarithromycin                                   | Oral: 250 mg and 500 mg base tablet<br>125 mg/5 mL and 250 mg/5 mL granules/powder for suspension, 50 mL  |
| Clindamycin                                      | Oral: 150 mg and 300 mg capsule (as hydrochloride)<br>75 mg/5 mL granules for suspension, 60 mL (as palmitate hydrochloride)                            |

| Active Ingredient                                  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | Inj.: 150 mg/mL, 2 mL ampul/vial and 4 mL ampul (IM, IV) (as phosphate)  |
| Clobetasol (as propionate)                         | Cream or Ointment: 0.05%, 5 g and 15 g tube<br>Shampoo: 0.05%, 25 mL bottle  |
| Clofazimine (B)                                    | Oral: 50 mg and 100 mg capsule (available under DOH program)   |
| Clomifene (1, 2)                                   | Oral: 50 mg tablet (as citrate)  |
| Clonazepam (A1)                                    | Oral: ⊗500 micrograms and 2 mg tablet  |
| Clonidine  | Oral: 75 micrograms and 150 micrograms tablet (as hydrochloride)<br>Inj.: 150 micrograms/mL, 1 mL ampul (IV) (as hydrochloride)  |
| Clopidogrel  | Oral: 75 mg tablet   |
| Clotrimazole                                       | Cream: 1% (10 mg/ g), 3 g, 10 g and 20 g aluminum collapsible tube<br>2% (20 mg/ g), 30 g aluminum collapsible tube<br>Vaginal Cream:<br>1%, 10 g aluminum collapsible tube<br>Ear Solution:<br>1% otic solution   |
| Cloxacillin (as sodium salt)                       | Oral: 500 mg capsule<br>250mg/ 5mL powder for oral solution, 60 mL   |
| Clozapine (1, 2)                                   | Oral: 25 mg and 100 mg tablet (requires hematologic monitoring)  |
| Co-Amoxiclav (amoxicillin + potassium clavulanate) | Oral: 500 mg amoxicillin (as trihydrate) + 125 mg potassium clavulanate per tablet<br>875 mg amoxicillin (as trihydrate) + 125 mg potassium clavulanate per tablet<br>200 mg amoxicillin (as trihydrate) + 28.5 mg potassium clavulanate per 5 mL granules/powder for suspension, 70 mL<br>400 mg amoxicillin (as trihydrate) + 57 mg potassium clavulanate per 5 mL granules/powder for suspension, 70 mL<br>600 mg amoxicillin (as trihydrate) + 42.9 mg potassium clavulanate per 5 mL granules/powder for suspension |
| Cobra Antivenin                                    | Inj.: 800 MU/ 4.8 mL, 1 mL ampul (for IV infusion)<br>800 IU/mL, 5 mL ampul (IV infusion) (1, 2)   |
| Codeine (A1)                                       | Oral: 30 mg MR capsule (as phosphate)  |

| Active Ingredient                               | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | 10 mg/5 mL, 60 mL suspension  |
| Colchicine                                      | Oral: 500 microgram tablet  |
| Colistin<br><b>*Reserve Antimicrobial</b>       | Inj.: 2,000,000 IU lyophilized powder for injection (IV infusion)   |
| Combined Glucose-Amino Acid Solutions           | Volume — 100 mL and 500 mL<br>Concentration — variable<br>Glucose (Sorbitol) — 25 - 50 g<br>Protein — 20 - 30 g<br>Calories — 300 - 450 Kcal<br>Electrolytes — variable   |
| Conjugated Estrogen                             | Oral: 625 micrograms and 1.25 mg tablet   |
| Cotrimoxazole (sulfamethoxazole + trimethoprim) | Oral: 400 mg sulfamethoxazole + 80 mg trimethoprim tablet/capsule (B)<br>800 mg sulfamethoxazole + 160 mg trimethoprim tablet (B)<br>200 mg sulfamethoxazole + 40 mg trimethoprim/ 5 mL suspension, 70mL and 120mL<br>400 mg sulfamethoxazole + 80 mg trimethoprim per 5 mL suspension, 60 mL<br>Inj.: 400 mg sulfamethoxazole + 80 mg trimethoprim, 5 mL ampul (IV infusion) |
| Crotamiton                                      | Lotion: 10%, 60 mL bottle   |
| Cyclophosphamide (1, 2)                         | Inj.: powder, 200 mg, 500 mg and 1 g vial (IV)  |
| Cycloserine                                     | Oral: 250 mg capsule  |
| Cyproterone (as acetate) (1, 2)                 | Oral: 50 mg tablet  |
| Cytarabine (1, 2)                               | Inj.: 20 mg/mL, 5 mL ampul (IM, SC, intrathecal)<br>100 mg/mL solution for injection, 1 mL, 5mL and 10 mL   |
| <b>D</b>  |   |
| Dacarbazine (1, 2)                              | Inj.: powder, 100 mg and 200 mg vial (IV, IV infusion)  |
| Daclatasvir                                     | Oral: 60 mg tablet  |
| Dactinomycin (1, 2)                             | Inj.: powder, 500 micrograms vial (IV)  |
| Danazol (1)                                     | Oral: 200 mg capsule  |
| Dantrolene (as sodium salt)                     | Oral: 25 mg and 50 mg capsule (1)<br>Inj.: 20 mg (with mannitol 3 g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (1, 2)   |
| Dapsone (B)                                     | Oral: 100 mg tablet   |
| Deferiprone (1, 2)                              | Oral: 500 mg tablet   |
| Deferasirox                                     | Oral: 125 mg and 250 mg dispersible tablets   |
| Deferoxamine (as mesilate)                      | Inj.: powder, 500 mg vial (IM, IV infusion, SC)   |

| Active Ingredient                           | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| (1, 2)                                      |  |
| Delamanid                                   | Oral: 50 mg film coated tablet (For use by the National Tuberculosis Control Program (NTP) of the Department of Health (DOH) only.)  |
| Desflurane (1)                              | Inhalation:<br>240 mL bottle   |
| Desmopressin (as acetate)                   | Oral: 100 micrograms and 200 micrograms tablet<br>Inj.: 15 micrograms/mL, 1 mL ampul (IM, SC) (as acetate)   |
| Dexamethasone                               | Oral: 500 micrograms, 750 micrograms, 3 mg and 4 mg tablet<br>Inj.: 4 mg/mL, 1 mL and 2 mL ampul/vial (IM, IV) (as sodium phosphate)<br>5 mg/mL, 1 mL ampul (IM, IV) (as sodium phosphate)<br>Eye Drops Suspension:<br>0.1%, 5 mL bottle |
| Dextran, High Molecular Weight (Dextran 70) | Inj.: 6% dextran 70 in 0.9% sodium chloride, 500 mL bottle (IV infusion)<br>6% dextran 70 in 5% dextrose, 500 mL bottle (IV infusion)  |
| Dextromethorphan (as hydrobromide) (2)      | Oral: 10 mg tablet   |
| 5% Dextrose in 0.3% Sodium Chloride         | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Dextrose — 50 g/L<br>Na <sup>+</sup> — 51 mmol/L<br>Cl <sup>-</sup> — 51 mmol/L   |
| 5% Dextrose in 0.45% Sodium Chloride        | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Dextrose — 50 g/L<br>Na <sup>+</sup> — 77 mmol/L<br>Cl <sup>-</sup> — 77 mmol/L   |
| 5% Dextrose in 0.9% Sodium Chloride         | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Dextrose — 50 g/L<br>Na <sup>+</sup> — 154 mmol/L<br>Cl <sup>-</sup> — 154 mmol/L   |

| Active Ingredient                              | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| 5% Dextrose in Lactated Ringers                | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion)<br><br>Composition:<br>Dextrose — 50 g/L<br>Na <sup>+</sup> — 130 mmol/L<br>K <sup>+</sup> — 4 mmol/L<br>Ca <sup>++</sup> — 1.22 – 1.5 mmol/L<br>Cl <sup>-</sup> — 109 mmol/L<br>Lactate — 28 mmol/L |
| 5% Dextrose in Water                           | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion and as vehicle for IV medications)  |
| 10% Dextrose in Water                          | Inj.: 250 mL, 500 mL and 1 L bottle/bag (IV infusion) 3 mL ampul (as solvent)  |
| Diazepam (1, A1)                               | Oral: ⊗ 5 mg tablet<br>Inj.: 5 mg/mL, 2 mL ampul (IM, IV)  |
| Diclofenac                                     | Oral: 25 mg and 50 mg tablet/capsule (as sodium or potassium salt)<br>50 mg enteric coated tablet or MR tablet (as sodium salt)<br>100 mg MR tablet/capsule (as sodium or potassium salt)<br>Inj.: 25 mg/mL, 3 mL ampul (IM, IV) (as sodium salt)          |
| Dicycloverine (Dicyclomine) (as hydrochloride) | Oral: 10 mg tablet<br>10 mg/5 mL syrup, 60 mL  |
| Diethylcarbamazine                             | Oral: 50 mg and 100 mg tablet (available under DOH program)  |
| Digoxin (2)                                    | Oral: 250 micrograms tablet<br>50 micrograms/mL elixir, 60 mL<br>Inj.: 250 micrograms/mL, 2 mL ampul (IM, IV)  |
| Diloxanide (as furoate)                        | Oral: 500 mg tablet (B)<br>125 mg/5 mL syrup/suspension, 30 mL and 60 mL   |
| Diltiazem (as hydrochloride)                   | Oral: 60 mg tablet<br>60 mg, 120 mg, 180 mg and 240 mg MR capsule (as hydrochloride)<br>120 mg and 180 mg MR tablet (as hydrochloride)   |
| Dimeglumine Gadopentetate                      | Inj.: 469 mg/mL aqueous solution, 5 mL, 10 mL and 20 mL vial   |
| Dimercaprol (1, 2)                             | Inj.: (in oil) 50 mg/mL, 2 mL ampul (IM)   |
| Dimercaptopropane-sulphonate (DMPS) (1, 2)     | Inj.: 100 mg/mL, 1 mL ampul and 10 mL vial (IM)  |
| Diphenhydramine (as hydrochloride)             | Oral: 25 mg and 50 mg capsule<br>12.5 mg/5 mL, 30 mL and 60 mL syrup   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | Inj.: 50 mg/mL, 1 mL ampul (IM, IV)   |
| Diphtheria Antitoxin  | Inj.: 10,000 IU and 20,000 IU, 5 mL and 10 mL (IV)  |
| Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus Influenza Type B (Hib) Combined Vaccine | Inj.: 0.5mL vial suspension for injection (IM)  |
| Diphtheria-Tetanus Toxoids (DT)   | Inj.: 30 IU diphtheria toxoid + 40 IU tetanus toxoid per 0.5 mL ampul (IM) (For less than 10 yrs. old)  |
| Diphtheria-Tetanus Toxoids (Td)   | Inj.: ≥ 2 IU diphtheria toxoid + ≥ 40 IU tetanus toxoid per 0.5 mL ampul (IM) (For 7 yrs. old and above)<br>≥ 2 IU diphtheria toxoid + ≥ 40 IU tetanus toxoid per 0.5 mL (IM), multidose vial (10 doses per vial)   |
| Diphtheria-Tetanus Toxoids and Acellular Pertussis Vaccines (DTaP)  | Inj.: 0.5 mL pre-filled syringe (IM)  |
| Diphtheria-Tetanus Toxoids and Pertussis Vaccine (DTP)  | Inj.: 0.5 mL ampul (IM)<br>0.5 mL pre-filled syringe (IM)<br>0.5 mL, 5 mL, 7.5 mL and 10 mL vial (IM)   |
| Dipyridamole (2)  | Oral: 25 mg tablet (preferably used in combination with aspirin)  |
| Divalproex Sodium<br>OR<br>Sodium Valproate + Valproic Acid   | Oral: 250 mg and 500 mg tablet<br>250 mg and 500 mg extended release (ER) tablet<br><br>Oral: 500 mg (333 mg sodium valproate + 145 mg valproic acid) controlled release tablet   |
| Dobutamine (1, 2)   | Inj.: 50 mg/mL, 5 mL ampul (concentrate) (IV infusion) (as hydrochloride)<br>2 mg/mL, 250 mL D5W (pre-mixed) (IV) (as hydrochloride)  |
| Docetaxel (1, 2)  | Inj.: 10 mg/mL solution for infusion (IV), 2 mL and 8 mL vial<br>20 mg/0.5 mL, 0.5 mL vial (IV infusion) (anhydrous)<br>40 mg/mL, 2 mL vial (IV infusion) (anhydrous)<br>20 mg/mL, 1mL concentrate for solution for IV infusion (as trihydrate)<br>80 mg/4mL, 4 mL concentrate for solution for IV infusion (as trihydrate) |
| Dolutegravir  | Oral: 50 mg tablet  |
| Domperidone   | Oral: 10 mg tablet<br>1 mg/mL suspension, 60 mL   |
| Donepezil   | Oral: 5 mg and 10 mg tablet/ orodispersible tablet (ODT)  |
| Dopamine (as hydrochloride) (1,   | Inj.: 40 mg/mL, 5 mL vial/ampul (IV)  |

| Active Ingredient                                | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
| 2)   | 800 micrograms/mL, 250 mL D5W (pre-mixed) (IV)<br>1.6 mg/mL, 250 mL D5W (pre-mixed) (IV)  |
| Dorzolamide                                      | Eye Drops Solution:<br>2%, 5 mL vial (as hydrochloride)   |
| Doxorubicin (as hydrochloride)<br>(1, 2)         | Inj.: powder, 10 mg and 50 mg vial (IV)<br>2 mg/mL, 5 mL and 25 mL vial (IV)  |
| Doxycycline                                      | Oral: 100 mg capsule (as hyclate)   |
| DTaP + Hib                                       | Inj.: 0.5 mL pre-filled syringe (IM)  |
| DTP + Hepatitis B Vaccine<br>(recombinant)       | Inj.: 0.5 mL vial (IM, SC)  |
| DTP + Hib  | Inj.: 0.5 mL DTP diluent in pre-filled syringe + freeze-dried, 10 microgram Hib vial (IM, SC)   |
| DTP + Inactivated Polio Vaccine<br>(IPV)         | Inj.: 0.5 mL monodose vial (IM, SC)<br>0.5 mL pre-filled syringe (IM, SC)   |
| DTP + IPV + Hib                                  | Inj.: 0.5 mL pre-filled syringe (IM, SC)  |
| Dydrogesterone                                   | Oral: 10 mg tablet  |
| <b>E</b>   |   |
| Efavirenz  | Oral: 50 mg, 100 mg, 200 mg and 600 mg tablet/capsule   |
| Emtricitabine + Tenofovir<br>Disoproxil Fumarate | Oral: 200 mg FDC Emtricitabine + 300 mg Tenofovir<br>Disoproxil Fumarate (fixed-dose combination)<br>tablet   |
| Enalapril (as maleate)                           | Oral: 5 mg and 20 mg tablet   |
| Enalapril + Hydrochlorothiazide                  | Oral: 20 mg enalapril + 12.5 mg hydrochlorothiazide<br>tablet   |
| Enoxaparin (as sodium salt) (1,<br>2)            | Inj.: 100 mg/mL, 0.2 mL, 0.4 mL and 0.6 mL pre-filled<br>syringe (SC)   |
| Entecavir  | Oral: 500 mcg and 1 mg tablet/ film-coated tablet<br>0.05 mg/mL oral solution   |
| Enteral Nutrition - Adult Polymeric              | Oral/Tube Feed:<br>Calories — 100 - 475 Kcal<br>Dilution — 1:1 - 2:1<br>Carbohydrates — 13.8 - 59 g<br>Protein — 3.8 - 19.9 g<br>Fat — 3.4 - 21.5 g<br>mOsm/kg — 270 - 730<br>Sodium — 75 - 402 mg<br>Potassium — 370 - 580 mg<br>Calcium — 80 - 500 mg<br>Magnesium — 25 - 500 mg<br>Fiber — 0 - 1.5 g |

| Active Ingredient                              | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | <p>Phosphorous — 47 - 307 mg<br/>Volume — 100 mL - 1 L</p>   |
| <p>Enteral Nutrition - Disease Specific</p>    | <p>Oral/Tube Feed:<br/>Calories — 100 - 1000 Kcal<br/>Dilution — 1:1 - 2:1<br/>Carbohydrates — 10.4 - 156 g<br/>Protein — 5.5 - 88 g<br/>Fat — 3.3 - 108 g<br/>mOsm/kg — 230 - 635<br/>Sodium — 80 - 2400 mg<br/>Potassium — 172 - 5600 mg<br/>Calcium — 80 - 500 mg<br/>Magnesium — 25 - 500 mg<br/>Phosphorous — 50 - 1789 mg<br/>Volume — 50 mL - 500 mL<br/>50 g - 500 g</p> |
| <p>Enteral Nutrition - Fiber Containing</p>    | <p>Oral/Tube Feed:<br/>Calories — 100 - 1048 Kcal<br/>Dilution — 1:1 - 2:1<br/>Carbohydrates — 13.8 - 148 g<br/>Protein — 3.8 - 40 g<br/>Fat — 3.4 - 34.7 g<br/>mOsm/kg — 270 - 375<br/>Sodium — 46.5 - 930 mg<br/>Potassium — 78.5 - 1570 mg<br/>Phosphorous — 63 - 720 mg<br/>Fiber — 2.0 - 10.6 g<br/>Volume — 500 mL<br/>100 g - 400 g</p>                                   |
| <p>Enteral Nutrition - Modular</p>             | <p>Oral:<br/>Calories — 9.5 - 380 Kcal<br/>Dilution — 0<br/>Carbohydrates — 0.67 - 94 g<br/>Protein — 5 - 23 g<br/>Fat — 0.6 g<br/>mOsm/kg — 900<br/>Sodium — 15 - 110 mg<br/>Potassium — 10 - 66 mg<br/>Phosphorous — 5 - 30 mg<br/>Volume — 280 g - 400 g</p>  |
| <p>Enteral Nutrition - Pediatric Polymeric</p> | <p>Oral:</p>   |



| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| Erythromycin  | Oral: 500 mg tablet (as stearate) (B)<br>200 mg/5 mL granules/powder for suspension,<br>60 mL (as ethyl succinate)<br>400 mg/5 mL granules/powder for suspension,<br>50 mL and 60 mL (as ethyl succinate)<br>Eye Ointment:<br>0.5%, 3.5 g and 5 g tube |
| Escitalopram (as oxalate)   | Oral: 10 mg tablet   |
| Esmolol (as hydrochloride) (1, 2)   | Inj.: 10 mg/mL, 10 mL vial (IV)<br>100 mg/mL, 10 mL vial (IV)  |
| Ethambutol (as hydrochloride)   | Oral: 100 mg tablet (pediatric)<br>200 mg and 400 mg tablet  |
| Ethinylestradiol + Desogestrel  | Oral: 30 micrograms ethinylestradiol + 150 microgram desogestrel per tablet  |
| Ethinylestradiol + Levonorgestrel   | Oral: 30 micrograms ethinylestradiol + 150 microgram levonorgestrel per tablet   |
| Ethinylestradiol + Norethisterone   | Oral: 35 micrograms ethinylestradiol + 400 microgram norethisterone acetate per tablet   |
| Ethinylestradiol + Norgestrel   | Oral: 30 micrograms ethinylestradiol + 300 microgram norgestrel per tablet   |
| Etonogestrel  | 68 mg subdermal implant  |
| Etoposide (1, 2)  | Inj.: 20 mg/mL, 5 mL ampul/vial (IV)<br>20 mg/mL, 10 mL vial (IV) powder 100 mg vial (IV)  |
| Everolimus  | Oral: 250 mcg and 500 mcg tablet   |
| <b>F</b>  |  |
| Factor IX Complex Concentrate (coagulation factors II, VII, IX, X) (1, 2) | Inj.: 100 IU/mL, 5 mL and 10 mL vial (IV) lyophilized powder, 500 IU vial + diluent (IV)   |
| Factor VIII Concentrate (1, 2)  | Inj.: lyophilized powder, 100 IU/g vial + diluent (IV)   |
| Famotidine  | Oral: 20 mg tablet<br>Inj.: 20 mg powder/lyophilized powder for injection, ampule/vial   |
| Felodipine  | Oral: 5 mg and 10 mg MR tablet   |
| Fenofibrate (1)   | Oral: 200 mg capsule<br>160 mg tablet  |
| Fentanyl (as citrate) (A1)  | Oral: 100 mcg, 200 mcg, 300 mcg and 400 mcg sublingual (SL) tablets<br>Inj.: 50 micrograms/mL, 2 mL and 10 mL ampul (IV)   |
| Ferrous Salt  | Oral: tablet, (equiv. to 60 mg elemental iron) solution, (equiv. to 15 mg elemental iron/0.6 mL) drops, 15 mL and 30 mL  |

| Active Ingredient                  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|------------------------------------|--|
|                                    | <p>solution, (equiv. to 30 mg elemental iron/5 mL)<br/>syrup, 60 mL</p> <p>N.B.: The elemental iron content of a ferrous salt depends on the type of preparation as follows:</p> <p>Ferrous fumarate – 33%<br/>Ferrous gluconate – 12%<br/>Ferrous lactate – 19%<br/>Ferrous lactate, hydrated – 20%<br/>Ferrous sulfate, desiccated – 32%</p> |
| Ferrous Salt + Folic Acid          | Oral: 60 mg elemental iron + 400 microgram folic acid per tablet/ capsule/film coated tablet   |
| Filgrastim (G-CSF) (1, 2)          | Inj.: 150 micrograms/0.6 mL, vial (IV, SC)<br>300 mcg/0.5 mL solution for injection in pre-filled syringe (IV, SC)<br>300 micrograms/mL, vial (IV, SC) 300 micrograms/1.2 mL, vial (IV, SC)  |
| Finasteride                        | Oral: 5 mg tablet  |
| Fluconazole                        | Oral: 50 mg, 150 mg and 200 mg capsule<br>Inj.: 2 mg/mL, 100 mL vial (IV infusion)   |
| Flucytosine (5-fluorocytosine) (1) | Oral: 250 mg tablet  |
| Flumazenil (1, 2)                  | Inj.: 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)   |
| Flunarizine (as hydrochloride)     | Oral: 5 mg capsule   |
| Fluocinonide                       | Cream or Ointment:<br>0.05%, 5 g and 15 g tube   |
| Fluorescein (as sodium salt)       | Inj.: 10% (100mg/mL), 5 mL ampul (IV)<br>Strips: 1 mg and 9 mg   |
| Fluorouracil (1, 2)                | Inj.: 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)   |
| Fluoxetine (1)                     | Oral: 20 mg dispersible tablet/capsule   |
| Flupentixol (as decanoate) (1)     | Inj.: 20 mg/mL, 1 mL ampul and 10 mL vial (IM)   |
| Fluphenazine (as decanoate) (1)    | Inj.: 25 mg/mL, 1 mL ampul and 10 mL vial (IM)   |
| Flutamide (1, 2)                   | Oral: 250 mg tablet  |
| Fluticasone (as propionate)        | <p>Nasal Aqueous Solution:<br/>0.05%/dose x 120 doses Inhalation:<br/>DPI: 50 micrograms/dose with appropriate accompanying dispenser<br/>250 micrograms/dose with appropriate accompanying dispenser</p>  |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
|  | MDI: 50 micrograms/dose x 60 doses and 120 doses<br>125 micrograms/dose x 60 doses and 120 doses<br>Resp. Soln.:<br>(for nebulization) 250 micrograms/mL, 2 mL<br>(unit dose)   |
| Fluticasone (as propionate) +<br>Formoterol (as fumarate<br>dihydrate) | Inhalation:<br>MDI: 50 mcg/5 mcg x 120 actuations 125 mcg/5 mcg x<br>120 actuations<br>250 mcg/10 mcg x 120 actuations  |
| Fluticasone (as propionate) +<br>Salmeterol (as xinafoate)             | Inhalation:<br>DPI: 100 micrograms fluticasone + 50 micrograms<br>salmeterol x 28 doses and 60 doses with<br>appropriate accompanying dispenser<br>250 micrograms fluticasone + 50 micrograms<br>salmeterol x 28 doses and 60 doses with<br>appropriate accompanying dispenser<br>500 micrograms fluticasone + 50 micrograms<br>salmeterol x 28 doses and 60 doses with<br>appropriate accompanying dispenser<br>MDI: 50 micrograms fluticasone + 25 micrograms<br>salmeterol x 120 actuations (with dose counter*)<br>125 micrograms fluticasone + 25 micrograms<br>salmeterol x 120 actuations (*)<br>250 micrograms fluticasone + 25 micrograms<br>salmeterol x 120 actuations (*) |
| Folic Acid   | Oral: 400 mcg, 800 mcg, 1 mg and 5 mg tablet /capsule<br>2.5mg/mL pediatric drops<br>5mg/5mL syrup  |
| Fomepizole (4 – methylprazole)<br>(1, 2)                               | Inj.: 1 g/mL, 1.5 mL vial (IV)  |
| Fondaparinux (as sodium salt)  | Inj.: 2.5 mg/0.5 mL solution  |
| Formoterol   | Inhalation:<br>DPI: 12 mcg dry powder for inhalation  |
| Fosfomycin   | Oral: 3 g granules for solution   |
| Furosemide   | Oral: 20 mg and 40 mg tablet (B)<br>Inj.: 10 mg/mL, 2 mL ampul (IM, IV)<br>10 mg/mL, 25 mL ampul (IV infusion)  |
| Fusidate Sodium / Fusidic Acid   | Cream: 2%, 5g tube<br>Ointment:<br>2%, 15g tube<br>Eye Drops Suspension:<br>1%, 5 g tube (as sulfate)   |

| Active Ingredient                     | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---------------------------------------|--|
| <b>G</b>                              |  |
| Gabapentin                            | Oral: 100 mg and 300 mg capsule  |
| Gadobutrol                            | Inj.: 1.0 mmol/mL solution for injection, 15 mL vial<br>1.0 mmol/mL solution for injection, 5 mL pre-filled syringe                        |
| Gadoteric acid                        | Inj.: 0.5 mmol/mL solution for injection, 10 mL, 15 mL and 20 mL vials   |
| Ganciclovir                           | Eye Gel: 0.15%, 5 g tube<br>Inj.: 500 mg vial (IV infusion) (as sodium) (1, 2)   |
| Gas Forming Agent                     | Oral:<br>Components per tablet:<br>Sodium bicarbonate — 470 mg<br>Glutamic acid — 70 mg<br>Tartaric acid — 420 mg<br>Silicon resin — 25 mg |
| Gemcitabine (as hydrochloride) (1, 2) | Inj.: 200 mg and 1 g vial (IV infusion)  |
| Gentamicin (as sulfate)               | Inj.: 10 mg/mL, 2 mL ampul/vial (IM, IV)<br>40 mg/mL, 2 mL ampul/vial (IM, IV)   |
| Gliclazide                            | Oral: 30 mg and 60 mg MR tablet<br>80 mg tablet  |
| Glucagon (as hydrochloride) (1, 2)    | Inj.: lyophilized powder, 1 mg + solvent (IM, IV, SC)  |
| Glucose (dextrose)                    | Inj.: 50%, 50 mL vial (IV)<br>50%, 10 mL and 20 mL ampul (IV)<br>50%, 10 mL, 20 mL and 50 mL (85 Kcal) vial (IV)                           |
| Glycerin (see Glycerol)               |  |
| Glycerol (glycerin)                   | Oral: USP grade (liquid)<br>Rectal: 2 g and 2.5 g suppository  |
| Glyceryl trinitrate (nitroglycerin)   | Inj.: 1 mg/mL, 10 mL and 25 mL ampul (IV infusion) (1, 2)  |
| Goserelin (as acetate)                | Inj.: 3.6 mg depot solution, pre-filled syringe (SC)<br>10.8 mg depot solution, pre-filled syringe (SC)                                    |
| <b>H</b>                              |  |
| Haloperidol (1)                       | Oral: 2 mg, 5 mg, and 10 mg tablet (B)<br>Inj.: 5 mg/mL, 1 mL ampul (IM)<br>50 mg/mL, 1 mL (oily) ampul (IM) (as decanoate)                |
| Halothane (1)                         | Inhalation: 250 mL bottle  |
| Hemodialysis Solution                 | 1) Acid Concentrates   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | <p>Composition:<br/>           Concentrates (g/L) Glucose – 0 – 49.5 g<br/>           Sodium chloride – 216.19 g – 270.8 g<br/>           Potassium chloride – 5.25 g – 6.7 g<br/>           Calcium chloride – 6.47 g – 9.9 g<br/>           Magnesium chloride – 3.58 g – 4.75 g<br/>           Glacial Acetic Acid – 8.1 g – 8.46 g<br/>           Purified Water – 1000 mL</p> <p>2) Sodium bicarbonate 650 g powder</p>                  |
| Hemophilus Influenzae type B Conjugated Vaccine (Hib)                       | <p>Inj.: 10 micrograms/0.5 mL, 1 dose vial + 0.5 mL diluent with tetanus protein (IM)<br/>           10 micrograms/0.5 mL vial + 0.9% sodium chloride with diphtheria CRM 197 protein (IM)<br/>           0.5 mL vial with meningococcal protein (IM)</p>   |
| Heparin (unfractionated) (as sodium salt) (1, 2)                            | <p>Inj.: 1000 IU/mL and 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)</p>   |
| Hepatitis A Inactivated Vaccine   | <p>Inj.: viral antigen not less than 720 EU in 0.5 mL monodose vial (IM) (junior)<br/>           viral antigen not less than 1440 EU in 1.0 mL monodose vial (IM) (adult)<br/>           80 units/0.5 mL (GBM strain) pre-filled syringe single dose (IM) (pediatric)<br/>           160 units/0.5 mL (GBM strain) pre-filled syringe single dose (IM) (adult)</p>  |
| Hepatitis B Immunoglobulin (human)  | <p>Inj.: 0.5 mL, 1 mL and 2 mL vial (IM)</p>  |
| Hepatitis B Vaccine (recombinant DNA)                                       | <p>Inj.: 10 micrograms/0.5 mL monodose vial (IM) (pediatric)<br/>           10 micrograms/0.5 mL, 5 mL (10 dose) vial (IM)<br/>           20 micrograms/mL monodose vial (IM) adult (For more than 10 years old)<br/>           20 micrograms/mL, 10 mL vial (10 doses/vial) adult</p> <p>N.B: Formulations of different manufacturers are of equal or similar immunogenicity. Follow strictly the recommended dose of each manufacturer.</p> |
| Human Papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine | <p>Inj.: 0.5 mL suspension, glass pre-filled syringe (IM)<br/>           0.5 mL glass vial</p>  |
| Human Papillomavirus vaccine types 16 and 18 (Recombinant,                  | <p>Inj.: 0.5 mL suspension in pre-filled syringe (type I</p>  |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
| AS04 Adjuvanted)  | glass)<br>with a plunger stopper (rubber butyl) with sterile needle<br>0.5 mL in 3 mL monodose type 1 glass vial 1 mL in 3 mL glass vial  |
| Human Recombinant Tissue Type Plasminogen Activator (Alteplase) (1) | Inj.: 50 mg powder for I.V. infusion  |
| Hydralazine (as hydrochloride)                                      | Oral: 25 mg and 50 mg tablet<br>Inj.: 20 mg/mL, 1 mL ampul (IM, IV)   |
| Hydrochlorothiazide   | Oral: 12.5 mg and 25 mg tablet  |
| Hydrocortisone  | Oral: 5 mg and 20 mg tablet<br>Inj.: 50 mg/mL, 2 mL vial (IM, IV) (as sodium succinate)<br>125 mg/mL, 2 mL vial (IV) (as sodium succinate)<br>powder, 100 mg and 250 mg vial (IV) (as sodium succinate)<br>Cream or Ointment:<br>1%, 5 g and 10 g tube (1)<br>Lotion: 1% and 2.5%, 25 mL bottle (1)   |
| Hydrogen Peroxide   | Solution:<br>3%, 60 mL and 120 mL bottle  |
| Hydroxychloroquine (as sulfate)                                     | Oral: 200 mg tablet   |
| Hydroxyethyl Starch   | Inj.: 6% solution, 250 mL and 500 mL bottle (IV infusion)   |
| Hydroxyurea (1, 2)  | Oral: 500 mg capsule  |
| Hydroxyzine (as dihydrochloride)                                    | Oral: 25 mg tablet<br>2 mg/mL syrup, 100 mL   |
| Hyoscine (as N-butyl bromide)                                       | Oral: 10 mg tablet<br>Inj.: 5 mg/5 mL syrup, 60 mL<br>20 mg/mL, 1 mL ampul (IM, IV, SC)   |
| Hypertonic lactate  | Inj.: Solution for IV infusion<br><br>Each 250 mL contains:<br><br>Sodium Lactate Solution (50%) - 28.250 g (equal with 14.125 Solution Lactate<br>Potassium Chloride - 0.075 g<br>Calcium Chloride 2H <sub>2</sub> O (100%) - 0.05 g Water for Injection - q.s.<br><br>Composition:<br>Na <sup>+</sup> - 504.15 mmol/L<br>K <sup>+</sup> - 40.2 mmol/L |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | Ca <sup>++</sup> - 1.36 mmol/L<br>Cl <sup>-</sup> - 6.74 mmol/L<br>Lactate - 504.15 mmol/L   |
| 3% Hypertonic Saline Solution<br>(for diagnosis of pulmonary tuberculosis) |  |
| Hypromellose   | Eye Drops Solution:<br>5 mg/mL and 10 mg/mL, 10 mL and 15 mL bottle<br>Ophthalmic Solution:<br>0.3%, 10 mL bottle  |
|  |  |
| Ibuprofen  | Oral: 200 mg and 400 mg tablet<br>100 mg/5 mL, 60 mL syrup/suspension<br>200 mg/5 mL, 60 mL suspension   |
| Idarubicin (as hydrochloride)<br>(1, 2)                                    | Inj.: powder, 5 mg vial (IV)   |
| Ifosfamide (1, 2)  | Inj.: powder, 1 g and 2 g vial (IV infusion)   |
| Imatinib (as mesilate) (1, 2)  | Inj.: 100 mg and 400 mg tablet   |
| Imiglucerase   | Inj: 400 U powder for intravenous infusion, 20 mL vial   |
| Imiquimod  | Cream: 5%, aluminum foil sachet  |
| Immunoglobulin Normal, Human<br>(IGIM)                                     | Inj.: 160 mg/mL, 2 mL, 5 mL and 10 mL vial (IM)  |
| Immunoglobulin Normal, Human<br>(IGIV) (1)                                 | Inj.: 50 mg/mL, 10 mL, 20 mL, 50 mL, 100 mL and 200 mL vial (IV)<br>freeze-dried powder, 1 g/bottle + 33 mL and 50 mL reconstitution fluid (IV)<br>freeze-dried powder, 2.5 g/bottle + 100 mL reconstitution fluid (IV)<br>freeze-dried powder, 5 g/bottle + 100 mL diluent vial (IV)<br>freeze-dried powder, 10 g/bottle + 260 mL diluent vial (IV) |
| Inactivated Polio Vaccine (Types 1, 2, and 3), Salk                        | Inj: 0.5 mL per dose (suspension for injection) in 5 mL multidose vial (IM, SC)  |
| Inactivated Poliomyelitis Vaccine<br>(Types 1, 2 and 3)                    | Inj: 0.5 mL per dose, suspension for injection single-dose/multidose vial (IM, SC)   |
| Indacaterol (as maleate) +<br>glycopyrronium (as bromide)                  | Inhalation:<br>110 mcg + 50 mcg inhalation powder in hard capsules   |
| Indapamide   | Oral: 1.5 mg MR tablet   |
| Influenza Polyvalent Vaccine   | Inj.: 0.5 mL vial + pre-filled syringe diluent (IM)  |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | <p>0.5 mL suspension in a pre-filled syringe or ampul (IM) (adult)<br/>           15mcg/0.5mL, 5mL multidose glass vial<br/>           7.5 mcg/0.25 mL suspension for injection, 0.25 mL single dose pre-filled glass syringe</p> <p>N.B.: Strains as recommended by WHO</p>   |
| Insulin Glargine   | <p>Inj.: 100 IU/mL, 10 mL Vial<br/>           100 IU/mL, 3 mL Pre-filled Pen</p>   |
| Interferon Alfa 2B (human) (1, 2)                        | <p>Inj.: 3 million IU and 5 million IU per mL vial + diluent (IM, SC)</p>  |
| Intraocular Irrigating Solution (balanced salt solution) | <p>Solution:<br/>           15 mL, 250 mL and 500 mL bottle<br/>           Composition:<br/>           Sodium chloride — 0.64%<br/>           Potassium chloride — 0.075%<br/>           Calcium chloride — 0.048%<br/>           Magnesium chloride hexahydrate — 0.03%<br/>           Sodium acetate — 0.39%<br/>           Sodium citrate — 0.17%<br/>           Water for injection to make 100%</p> |
| Iodine   | <p>Oral: aqueous iodine solution (Lugol'ssolution)<br/>           5% iodine, 10 % potassium iodide (total iodine - 130 mg/mL), 30 mL</p> <p>Tincture:<br/>           1% and 2%</p> <p>Solution:<br/>           2% and 5%</p>   |
| Iodixanol  | <p>Inj.: 652 mg/mL (equivalent to 320 mg iodine) solution for injection, 50 mL and 100 mL vial<br/>           550 mg/mL (equivalent to 270 mg iodine) solution for injection, 50 mL vial</p>   |
| Iodized Oil Fluid  | <p>Oral: 500 mg (equiv. to 200 mg elemental iodine) softgel capsule <b>(only for DOH program)</b></p>  |
| Iohexol  | <p>Inj.: (Intravascular and other parenteral routes as appropriate)<br/>           300 mg iodine/mL, 50 mL and 100 mL vial<br/>           350 mg iodine/mL, 50 mL and 100 mL vial</p>  |
| Iopamidol  | <p>Inj.: (Intravascular and other parenteral routes as appropriate)<br/>           612 mg/mL equiv. to 300 mg iodine, 50 mL and 100</p>  |

| Active Ingredient                                      | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | mL vial<br>755 mg/mL equiv. to 370 mg iodine, 50 mL and 100 mL vial/bottle   |
| Iopromide  | Inj.: 300 mg/mL equiv. to 623 mg iodine, 50 mL and 100 mL vial<br>370 mg/mL equiv. to 769 mg iodine, 50 mL and 100 mL vial   |
| Iothalamate  | Inj.: 600 mg/mL, 30 mL, 50 mL and 100 mL vial (usually IV) (as meglumine)  |
| Ioversol   | Inj.: 636 mg/mL equiv. to 300 mg/mL iodine, 50 mL and 100 mL vial<br>741 mg/mL equiv. to 350 mg/mL iodine, 50 mL and 100 mL vial   |
| Ipratropium (as bromide)                               | Inhalation:<br>MDI: 20 micrograms/dose x 200 doses<br>Resp. Soln.: (for nebulization) 250 micrograms/mL, 2 mL (unit dose)  |
| Ipratropium (as bromide) + Fenoterol (as hydrobromide) | Inhalation:<br>MDI: 20 micrograms ipratropium + 50 micrograms fenoterol x 10 mL doses  |
| Ipratropium + Salbutamol                               | Inhalation:<br>MDI: 20 micrograms ipratropium (as bromide) + 100 micrograms salbutamol x 200 doses x 10mL<br>Resp. Soln.: (for nebulization)<br>500 micrograms ipratropium (as bromide anhydrous) + 2.5 mg salbutamol (as base) x 2.5 mL (unit dose) |
| Irbesartan   | Oral: 150 mg and 300 mg tablet   |
| Irbesartan + Hydrochlorothiazide                       | Oral: 150 mg irbesartan + 12.5 mg hydrochlorothiazide tablet   |
| Irinotecan (as hydrochloride) (1, 2)                   | Inj.: 40 mg/2 mL concentrate, vial (IV infusion)<br>100 mg/5 mL concentrate, vial (IV infusion)  |
| Iron sucrose   | Inj.: 20 mg/mL, 5 mL ampule  |
| Isoflurane (1)   | Inhalation:<br>100 mL and 250 mL bottle  |
| Isoniazid  | Oral: 300 mg and 400 mg tablet<br>200 mg/5 mL syrup, 120 mL  |
| Isoniazid + Rifampicin (B)                             | Oral: 50 mg + 75 mg dispersible fixed dose combination tablet (pediatric)<br>75 mg + 150 mg tablet   |

| Active Ingredient                                      | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
| Isoniazid + Rifampicin + Ethambutol (B)                | Oral: 75 mg + 150 mg + 275 mg tablet  |
| Isoniazid + Rifampicin + Pyrazinamide (B)              | Oral: 50 mg + 75 mg + 150 mg dispersible fixed dose combination tablet (pediatric)  |
| Isoniazid + Rifampicin + Pyrazinamide + Ethambutol (B) | Oral: 75 mg + 150 mg + 400 mg + 275 mg tablet   |
| Isothane Insulin Human (recombinant DNA)               | Inj.: 100 IU/mL, 3 mL pre-filled syringe (SC)<br>100 IU/mL, 5 mL and 10 mL vial (SC)  |
| Isosorbide Dinitrate                                   | Oral: 10 mg and 20 mg tablet 20 mg MR tablet/capsule<br>Sublingual:<br>5 mg tablet<br>Inj.: 1 mg/mL, 10 mL ampul (IV) (I)   |
| Isosorbide-5-Mononitrate                               | Oral: 40 mg tablet<br>30 mg and 60 mg MR tablet/capsule   |
| Istonic electrolyte solution for IV infusion           | Each 1 liter (L) of the product contains:<br><br>Sodium chloride – 6.80 g<br>Potassium chloride – 0.30 g<br>Calcium chloride dihydrate – 0.37 g<br>Magnesium chloride hexahydrate – 0.20 g<br>Sodium acetate trihydrate – 3.27 g<br>Malic acid – 0.67 g |
| Isoxsuprine (as hydrochloride)                         | Oral: 10 mg and 40 mg tablet<br>Inj.: 5 mg/mL, 2 mL ampul (IM, IV infusion)   |
| Itraconazole   | Oral: 100 mg capsule  |
| Ivermectin   | Oral: 3 mg and 6 mg tablet  |
| <b>K</b>   |   |
| Kanamycin (as sulfate)                                 | Inj.: 1 g vial (IM)   |
| Ketamine (as hydrochloride) (1, A1)                    | Inj.: ⊗ 50 mg/mL, 10 mL vial (IM, IV)   |
| Ketoconazole   | Cream: 2% (20 mg/g), 3.5 g and 15 g aluminum collapsible tube<br>Shampoo:<br>2% (20 mg/g), 6 mL foil sachet, 10 mL, 60 mL and 100 mL bottle   |
| Ketoprofen   | Oral: 100 mg tablet<br>Inj.: 50 mg/mL, 2 mL ampul (IM)  |
| Ketorolac (as tromethamol)                             | Inj.: 30 mg/mL, 1 mL ampul (IM, IV)   |
| <b>L</b>   |   |
| Lactated Ringer's Solution                             | Inj.: 500 mL and 1 L bottle/bag (IV infusion)   |

| Active Ingredient                                   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
| (Ringer's Lactate)                                  | <p>Composition:<br/>           Na<sup>+</sup> — 130 mmol/L<br/>           K<sup>+</sup> — 4 mmol/L<br/>           Ca<sup>++</sup> — 1.22 – 1.5 mmol/L<br/>           Cl<sup>-</sup> — 109 mmol/L<br/>           Lactate — 28 mmol/L</p>   |
| Lactulose   | Oral: 3.3 g/5 mL (3.35 g/5 mL) syrup  |
| Lagundi • [Vitex negundo L.<br>( Fam. Verbenaceae)] | Oral: 300 mg and 600 mg tablet<br>300 mg/5 mL syrup, 60 mL and 120 mL bottle<br>600 mg/5 mL syrup, 60 mL and 120 mL bottle  |
| Lamivudine  | Oral: 100 mg and 150 mg tablet/film coated tablet<br>10mg/mL suspension, 240mL bottle   |
| Lamivudine + Efavirenz + Tenofovir                  | Oral: 300 mg + 600 mg + 300 mg tablet   |
| Lamivudine +Tenofovir                               | Oral: 300 mg + 300 mg tablet  |
| Lamivudine + Zidovudine                             | Oral: 150 mg + 300 mg tablet  |
| Lamivudine + Zidovudine + Nevirapine                | Oral: 150 mg + 300 mg + 200 mg tablet   |
| Lamotrigine   | Oral: 50 mg and 100 mg tablet   |
| Lansoprazole  | Oral: 15 mg and 30 mg capsule<br>15 mg and 30 mg MR tablet  |
| Latanoprost   | Eye Drops Solution:<br>50 micrograms/mL, 2.5 mL bottle  |
| Latanoprost + Timolol maleate                       | Ophthalmic Solution:<br>50 mcg + 5 mg/mL, 5 mL bottle   |
| Letrozole   | Oral: 2.5 mg tablet/film-coated tablet  |
| Leucovorin Calcium (see Calcium Folate) (1, 2)      | Inj.: 10 mg/mL, 5 mL ampul/vial (IM, IV)<br>50 mg vial (IM, IV)   |
| Leuproreline (as acetate) (1, 2)                    | Inj.: 3.75 mg/ 2 mL vial with syringe (IM, SC)<br>powder, 1.88 mg single dose with syringe (IM, SC)<br>powder, 3.75 mg single dose with syringe (IM, SC)<br>powder, 11.25 mg depot solution, vial with syringe (IM, SC)<br>7.5 mg, 22.5 mg and 45 mg in pre-filled syringe (SC) |
| Levetiracetam                                       | Oral: 250 mg, 500 mg, 750 mg, and 1 g film coated tablet<br>Inj.: 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial<br><br>Solution:<br>100 mg/mL oral solution, 100 mL and 300 mL bottle   |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| Levobupivacaine  | Inj.: 5 mg/mL solution for injection, 10 mL ampule   |
| Levodopa + Carbidopa                                       | Oral: 100 mg levodopa + 25 mg carbidopa per tablet<br>250 mg levodopa + 25 mg carbidopa per tablet<br>200 mg levodopa + 50 mg carbidopa extended release tablet  |
| Levofloxacin   | Oral: 250 mg, 500 mg and 750 mg tablet<br>Inj.: 5 mg/mL solution for IV infusion, 100 mL and 150 mL<br><br>vial<br>Eye Drops:<br>5 mg/mL (0.5% w/v) ophthalmic solution  |
| Levothyroxine (as sodium/anhydrous sodium)                 | Oral: 50 mcg, 100 mcg and 150 mcg tablet   |
| Lidocaine (as hydrochloride) (1, 2)                        | Inj.: 1%, 20 mL ampul<br>2% (20 mg/mL), 2 mL, 5 mL, 20 mL and 50 mL ampul/vial (IM/IV)<br>2%, 5 mL and 50 mL vial (epidural, local infiltration)<br>2%, 1.8 mL carpule (with epinephrine) (local infiltration) Spray: 10%, 50 mL |
| Linezolid<br><b>*Reserve Antimicrobial</b>                 | Oral: 600 mg tablet/film-coated tablet<br>Inj.: 2 mg/mL (600 mg/300 mL), solution for infusion (IV)  |
| Lipids   | Inj.: 10%, 100 mL, 200 mL and 500 mL bottle (IV infusion)<br>20%, 100 mL, 250 mL and 500 mL bottle (IV infusion)   |
| Lithium Carbonate (1)                                      | Oral: 450 mg MR tablet   |
| Live Attenuated Bivalent Oral Polio Vaccine (Type 1 and 3) | Oral: 2 mg vial (20 doses)   |
| Live Attenuated Measles Vaccine                            | Inj.: monodose vial + 0.5 mL diluent (SC)<br>multidose vial + 5 mL diluent (SC)  |
| Live Attenuated Measles, Mumps and Rubella (MMR) Vaccine   | Inj.: monodose vial + 0.5 mL diluent (SC) multidose vial +<br><br>5 mL diluent (SC)  |
| Live Attenuated Measles and Rubella (MR) Vaccine           | Inj.: multidose vial (10 doses/vial) + 5 mL diluent (SC), with vaccine vial monitor (VVM)  |
| Live Attenuated Mumps Vaccine                              | Inj.: monodose vial + 0.5 mL diluent (SC)  |
| Live Attenuated Rubella Vaccine                            | Inj.: monodose vial + 0.5 mL diluent (SC)<br>multidose vial + 5 mL diluent (SC)  |
| Live Attenuated Varicella Vaccine                          | Inj.: freeze-dried powder, not less than 2000 PFU (OKA strain varicella zoster virus)<br>monodose vial + diluent (0.5 mL water for injection) ampul (SC only)  |
| Loperamide (as hydrochloride)                              | Oral: 2 mg capsule   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | (N.B.: Not for infants and children less than 12 years old)   |
| Lopinavir + Ritonavir   | Oral: 200 mg + 50 mg tablet/capsule<br>40 mg + 10 mg oral pellets contained in capsule  |
| Loratadine  | Oral: 10 mg tablet/film coated tablet<br>5 mg/5 mL syrup, 30 mL   |
| Losartan (as potassium salt)                                  | Oral: 50 mg and 100 mg tablet   |
| Losartan + Hydrochlorothiazide                                | Oral: 50 mg losartan + 12.5 mg hydrochlorothiazide tablet   |
| Lynestrenol   | Oral: 500 mcg tablet  |
| <b>M</b>  |   |
| Magnesium Sulfate (as heptahydrate) (1, 2)                    | Inj.: 250 mg/mL, 2 mL and 10 mL ampul (IM, IV)<br>250 mg/mL, 10 mL, 20 mL and 50 mL vial (IV)<br>500 mg/mL, 2 mL and 10 mL ampul (IM, IV)   |
| Mannitol  | Inj.: 20%, 250 mL and 500 mL bottle (IV)  |
| Mebendazole   | Oral: 100 mg tablet/capsule<br>500 mg tablet/chewable tablet<br>50 mg/mL suspension, 10 mL<br>100 mg/5 mL suspension, 30 mL and 60 mL   |
| Mebeverine (as hydrochloride)                                 | Oral: 100 mg tablet   |
| Mecobalamin   | Oral: 500 microgram tablet<br>Inj.: 500 micrograms/mL, 1 mL ampul (IM, IV)  |
| Medroxyprogesterone (2)                                       | Oral: 5 mg and 10 mg tablet (as acetate)<br>Inj.: 50 mg/mL, 3 mL vial + syringe (IM) (as acetate)<br>(N.B. Use one (1) inch long needle)<br>150 mg/mL, 1 mL vial (IM) (as enanthate or acetate)   |
| Mefenamic Acid  | Oral: 250 mg and 500 mg tablet/capsule  |
| Mefloquine (as hydrochloride) (B)                             | Oral: 250 mg tablet   |
| Megestrol (as acetate) (1, 2)                                 | Oral: 40 mg and 160 mg tablet   |
| Melphalan (1, 2)  | Oral: 2 mg tablet   |
| Memantine   | Oral: 5 mg and 10 mg film coated tablet   |
| Meningococcal polysaccharide (Neisseria meningitidis) vaccine | Inj.: lyophilized powder, 50 micrograms/ 0.5 mL dose (Group A + C) multidose (10 doses) + 5 mL diluent vial (IM, SC)<br>lyophilized powder, 50 micrograms/ 0.5 mL dose (Group A + C) single dose + 0.5 mL diluent syringe (IM, SC)<br>lyophilized powder, 50 micrograms/ 0.5 mL dose (Serogroup A + Serogroup B + Serogroup W135) |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
|   | + Serogroup Y) multidose (10 doses) + diluent vial (IM, SC)  |
| Mercaptopurine (1, 2, B)  | Oral: 50 mg tablet   |
| Meropenem (as trihydrate)<br><b>*Reserve Antimicrobial</b>                | Inj.: 500 mg and 1 g powder, vial (IV)   |
| Mesalazine (1)  | Oral: 500 mg enteric coated tablet<br>500 mg enteric MR tablet<br>Rectal: 250 mg suppository<br>Sachet: 1.5 g gastro-resistant prolonged release (PR) granules   |
| Mesna (sodium-2-mercaptopethanesulphonate) (1, 2)                         | Inj.: 100 mg/mL, 4 mL ampul (IV)   |
| Metformin (as hydrochloride)  | Oral: 500 mg tablet/film coated tablet 850 mg tablet   |
| Methimazole (thiamazole)  | Oral: 5 mg and 10 mg tablet  |
| Methotrexate (1)  | Oral: 2.5 mg tablet (as base, sodium salt or disodiumsalt)<br>Inj.: 5 mg/mL, 3 mL vial (IM, IV) (as sodium salt)<br>25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)<br>25 mg/mL, 2 mL and 20 mL vial (IM, IV, Intrathecal) (as sodium salt, preservative-free)<br>100 mg/mL, 10 mL vial (as base)<br>100 mg/mL, 10 mL vial (IM, IV, Intrathecal) (as sodium salt, preservative-free) |
| Methyldopa  | Oral: 250 mg tablet  |
| Methylene Blue (1, 2)   | Oral: 1% solution<br>Inj.: 10 mg/mL, 1 mL and 10 mL ampul/vial   |
| Methylergometrine (methylegonovine) (as hydrogen maleate or maleate) (A2) | Inj.: 200 micrograms/mL, 1 mL ampul (IM, IV)   |
| Methylegonovine (see Methylergometrine)                                   |  |
| Methylphenidate (1, 2, A1)  | Oral: 10 mg tablet<br>18 mg, 27 mg and 36 mg MR tablet 20 mg modified release capsule  |
| Methylprednisolone  | Oral: 4 mg and 16 mg tablet<br>Inj.: powder, 125 mg/mL, 2 mL vial + diluent vial (IM, IV, IV infusion) (as sodium succinate)<br>40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)<br>powder, 500 mg, 7.7 mL vial (IV) + diluent vial (IM, IV, IV infusion) (as sodium succinate)<br>powder, 1 g/16 mL vial + diluent vial (IM, IV, IV                           |

| Active Ingredient                           | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|---|---|
|   | infusion) (as sodium succinate)<br>lyophilized powder, 125 mg vial (IM, IV) (as sodium succinate)<br>lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)<br>lyophilized powder, 1 g vial (IM, IV) (as sodium succinate)<br>powder, 500 mg/8.0 mL vial + diluent vial (IM, IV, IV infusion) (as sodium succinate) |
| Metoclopramide                              | Oral: 10 mg tablet (as hydrochloride)<br>5 mg/5 mL syrup, 60 mL (as base and as hydrochloride)<br>Inj.: 5 mg/mL, 2 mL ampul (IM, IV) (as base and as hydrochloride)   |
| Metoprolol (as tartrate)                    | Oral: 50 mg and 100 mg tablet   |
| Metronidazole                               | Oral: 250 mg and 500 mg tablet<br>125 mg base/5 mL (200 mg/5 mL (as benzoate)) suspension, 60 mL<br>Inj.: 5 mg/mL, 100 mL vial (IV infusion)  |
| Miconazole<br><b>*Reserve Antimicrobial</b> | Inj.: 50 mg lyophilized powder for infusion (IV)  |
| Miconazole                                  | Oral gel:<br>20 mg, 3.5 g aluminum tube<br>Topical Cream:<br>2% (20 mg/g), 5 g aluminum collapsible tube<br>Vaginal suppository:<br>1.2 g, casing strip x 1's   |
| Micronutrient Powder                        | Per 1 gram sachet:<br>Vitamin A - 400 ug RE<br>Vitamin C - 30 mg<br>Vitamin D - 5 ug<br>Vitamin E - 5 mg a-TE<br>Vitamin B1 - 0.5 mg<br>Vitamin B2 - 0.5 mg<br>Vitamin B6 - 0.5 mg<br>Vitamin B12 - 0.9 ug<br>Folic acid - 150 ug<br>Niacin - 6 mg<br>Iron - 10 mg<br>Zinc - 4.1 mg<br>Copper - 0.56 mg<br>Iodine - 90 ug S |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
|  | elenium - 17 ug   |
| Midazolam (A1)   | Oral: ⊗15 mg tablet<br>Inj.: 1 mg/mL, 5 mL ampul/vial (IM, IV)<br>5 mg/mL, 1 mL, 2 mL, 3 mL, 5 mL and 10 mL ampul (IM, IV)                                  |
| Mitoxantrone (1, 2)  | Inj.: 2 mg/mL solution, 5 mL and 10 mL  |
| Modified Fluid Gelatin (polymerisate of degraded succinylated gelatin) | Inj.: 3% and 4% solution, 500 mL bottle (IVinfusion)  |
| Monobasic/Dibasic Sodium Phosphate                                     | Oral: 48 g/18 g per 100 mL solution, 45 mL bottle<br>Rectal: 19 g/7 g solution per 133 mL and 66 mL bottle (enema)  |
| Montelukast (as sodium salt) (1)                                       | Oral: 4 mg granules, sachet<br>4 mg and 5 mg chewable tablet<br>10 mg tablet  |
| Morphine (as sulfate) (A1)   | Oral: 10 mg, 20 mg and 30 mg tablet/capsule<br>10 mg, 30 mg, and 60 mg MRtablet<br>Inj.: 10 mg/mL, 1 mL ampul (IM, IV, SC)<br>16 mg/mL, 1 mL ampul (IM, IV) |
| Moxifloxacin   | Oral: 400 mg film coated tablet<br>Ophthalmic solution:<br>5 mg/mL (0.5% w/v) sterile ophthalmic solution, 5 mL bottle (as hydrochloride)                   |



| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
|   | 250 mg/5 mL suspension, 60 mL  |
| Naloxone (as hydrochloride) (1, 2)  | Inj.: 400 micrograms/mL, 1 mL ampul (IM, IV, SC)   |
| Naltrexone (as hydrochloride)   | Oral: 50 mg tablet   |
| Naproxen (as sodium salt)   | Oral: 250 mg base (275 mg) and 500 mg base (550mg) tablet  |
| Neomycin (as sulfate) + Polymixin B (as sulfate) + Fluocinolone Acetonide | Ear Drops Solution:<br>3.5 mg neomycin + 10,000 units polymyxin B + 0.025% fluocinolone acetonide/mL, 5  |
| Neostigmine   | Inj.: 500 mcg/mL, 10 mL vial<br>500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule  |
| Nepafenac   | Eye Suspension:<br>1 mg/mL, 5 mL bottle  |
| Nevirapine  | Oral: 200 mg tablet (B)<br>50 mg dispersible tablet<br>50 mg/5 mL suspension, 240 mL   |
| Nicardipine (as hydrochloride) (1)  | Inj.: 1 mg/mL, 2 mL and 10 mL ampul (IV)   |
| Nicotine  | Pastille:<br>1 mg and 2 mg<br>Gum: 1 mg and 2 mg   |
| Nicotine transdermal therapeutic system                                   | Patch: 7 mg , 14 mg and 21 mg patch  |
| Nifedipine  | Oral: 10 mg capsule (B) (restricted use for acute hypertensive emergencies in patients less than 18 years old with extreme caution due to rapid and prolonged fall in blood pressure)<br>30 mg MR tablet |
| Nimodipine  | Oral: 30 mg tablet   |
| Nitrofurantoin (B)  | Oral: 50 mg and 100 mg capsule (asmacrocrytals)  |
| Nitroglycerin (see Glyceryl Trinitrate)                                   | Inj.: 1 mg/mL, 10 mL and 25 mL ampul (IV infusion) (1, 2)  |
| Nitrous Oxide (1)   | Inhalation: Anesthetic gas   |
| Norepinephrine (as bitartrate) (1, 2)                                     | Inj.: 1 mg/mL, 2 mL and 4 mL ampul (IV infusion)<br>1 mg/mL, 10 mL ampule (concentrate solution for infusion)<br>2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection                                |
| Norethisterone (as acetate and as base) (2)                               | Oral: 5 mg tablet  |

| Active Ingredient                           | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| Nystatin                                    | Oral: 100,000 units/mL suspension, 30 mL<br>Vaginal:<br>100,000 units per tablet   |
| <b>O</b>                                    |  |
| Octreotide (as acetate) (1, 2)              | Inj.: 100 micrograms/mL and 500 micrograms/mL, 1 mL ampul (IV infusion)  |
| Ofloxacin                                   | Oral: 200 mg tablet<br>Eye Drops Solution:<br>0.3%, 5 mL bottle<br>Ear Drops Solution:<br>0.3%, 5 mL bottle  |
| Olanzapine (1, 2)                           | Oral: 5 mg and 10 mg tablet<br>10 mg orodispersible tablet (ODT)   |
| Olodaterol (as hydrochloride)               | Inhalation:<br>2.5 mcg/puff solution for inhalation, inhaler with 4 mL cartridge x 60 puffs (equiv. to 30 medicinal doses)   |
| Omeprazole                                  | Oral: 20 mg and 40 mg capsule<br>Inj.: powder, 40 mg vial + 10 mL solvent ampul/vial (IV)  |
| Ondansetron (1, 2)                          | Oral: 8 mg tablet (as hydrochloridedihydrate)<br>Inj.: 2 mg/mL, 2 mL and 4 mL ampul (IM,IV)  |
| Oral Rehydration Salts (ORS 75-replacement) | Oral: Composition of reduced osmolarity ORS per liter of water (WHO recommended):<br><br>Sodium chloride — 2.6 g<br>Trisodium citrate dihydrate — 2.9 g<br>Potassium chloride — 1.5 g<br>Glucose anhydrous — 13.5 g<br>Total Weight — 20.5 g<br><br>Reduced osmolarity ORS Equivalent in mmol/L:<br><br>Sodium — 75<br>Chloride — 65<br>Potassium — 20<br>Citrate — 10<br>Glucose anhydrous — 75<br>Total osmolarity — 245<br><br>N.B.: Reconstitute with clean potable water. |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
|  | Unused reconstituted solution shall be discarded after 24 hours.  |
| Oseltamivir (as phosphate)                                 | Oral: 75 mg capsule   |
| Oxacillin (as sodium salt)                                 | Inj.: 250 mg and 500 mg vial (IM, IV)   |
| Oxaliplatin (1, 2)   | Inj.: 5 mg/mL concentrate solution, 10 mL and 20 mL vial (IV infusion)<br>powder, 50 mg vial (IV infusion)  |
| Oxcarbazepine  | Oral: 300 mg and 600 mg tablet<br>60 mg/mL, 100 mL and 250 mL oral suspension   |
| Oxycodone (as hydrochloride) (A1)                          | Oral: 5 mg capsule<br>10 mg, 20 mg, 40 mg and 80 mg tablet/prolonged-release or controlled release tablet<br>Inj: 10 mg/mL, 1 mL and 2 mL ampule for IV infusion  |
| Oxycodone (as hydrochloride) + Naloxone (as hydrochloride) | Oral: 5 mg + 2.5 mg, 10 mg + 5 mg, 20 mg + 10 mg, 40 mg + 20 mg tablet (prolonged-release)  |
| Oxygen   | Inhalation: (medicinal gas)   |
| Oxymetazoline (as hydrochloride)                           | Nasal Drops Solution:<br>0.025%, 10 mL bottle Nasal Spray:<br>0.05%, 10 mL and 15 mL bottle   |
| Oxytocin (synthetic) (2)                                   | Inj.: 10 IU/mL, 1 mL ampul (IM, IV)   |
| <b>P</b>   |   |
| Paclitaxel (1, 2)  | Inj.: 6 mg/mL, 5 mL, 16.7 mL, 17 mL, 25 mL and 43.4 mL vial (IV, IV infusion)   |
| Paliperidone   | Inj.: 50 mg/0.5 mL, 75 mg/0.75 mL, 100 mg/mL and 150 mg/1.5 mL prolonged release suspension for injection (IM)  |
| Pancuronium (as bromide) (1)                               | Inj.: 2 mg/mL, 2 mL ampul (IM, IV)  |
| Pantoprazole   | Oral: 20 mg and 40 mg tablet/enteric-coated tablet  |
| Para-amino salicylic acid                                  | Sachet:<br>4 gram enteric coated delayed release granules in sachet   |
| Paracetamol  | Oral: 300 mg and 500 mg tablet<br>100 mg/mL drops, 15 mL (alcohol-free)<br>120 mg/5 mL (125 mg/5 mL) syrup/suspension, 30 mL, 60 mL and 120 mL (alcohol-free)<br>250 mg/5 mL syrup/suspension, 30 mL, 60 mL and 120 mL (alcohol-free)<br>Inj.: 150 mg/mL, 2mL ampule solution for injection (IM/IV)<br>10 mg/mL, 50 mL and 100 mL vial solution for |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
|   | infusion (IV)<br>Rectal: 125 mg and 250 mg suppository   |
| Peginterferon Alfa 2A (1, 2)  | Inj.: 135 micrograms/0.5 mL pre-filled syringe (SC)  |
| Penicillin G Benzathine (benzathine benzylpenicillin)               | Inj.: 1,200,000 units vial (MR) (IM)   |
| Penicillin G Crystalline (benzylpenicillin) (as sodium salt) (1, 2) | Inj.: 1,000,000 units vial (IM, IV)<br>5,000,000 units vial (IM, IV)   |
| Peritoneal Dialysis Solution  | Solution:<br>Sterile with 1.5%, 2.3 %, 2.5% and 4.25% dextrose, 2 L and 5 L bottle/bag<br><br>Content per liter:<br>Glucose Monohydrate – 16.5 g (equivalent to 15.0 g glucose)<br>Fructose – up to 0.75 g<br>Sodium chloride – 5.786 g<br>Sodium (S) – lactate solution (equivalent to 3.925 g sodium (S) – lactate) – 7.85 g<br>Calcium chloride dihydrate – 183.8 mg<br>Magnesium chloride hexahydrate – 101.7 mg |
| Permethrin  | Lotion: 1%, 125 mL bottle<br>5%, 30 mL and 60 mL bottle Shampoo (Creme Rinse):<br>1%, 30 mL and 60 mL bottle   |
| Pethidine (meperidine) (as hydrochloride) (A1)                      | Inj.: 50 mg/mL, 2 mL ampul (IM, IV, SC)  |
| Petrolatum/ petroleum   | Jelly: USP grade, 25 g, 100 g and 200 g jar  |
| Phenobarbital (A1)  | Oral: ⊗15 mg, 30 mg, 60 mg and 90 mg tablet<br>Inj.: 120 mg/mL (130 mg/mL), 1 mL ampul (IM, IV) (as sodium salt)   |
| Phenoxyethyl Penicillin (penicillin V) (as potassium salt)          | Oral: 250 mg and 500 mg tablet/capsule 250 mg/5 mL granules/powder for syrup/suspension, 60 mL   |
| Phenylephrine (as hydrochloride)                                    | Eye Drops Solution:<br>2.5%, 5 mL bottle   |
| Phenytoin (as sodium salt)  | Oral: 100 mg capsule (B)<br>30 mg/5 mL suspension, 120 mL<br>125 mg/ 5mL suspension, 120mL<br>Inj.: 50 mg/mL, 2 mL and 5 mL ampul (IV) (1)   |
| Phospholipid fraction from bovine lung                              | Inj.: 45 mg/mL (54 mg/1.2 mL) lyophilized powder for suspension (intratracheal administration)   |
| Physostigmine (as salicylate) (1, 2)                                | Inj.: 1 mg/mL, 2 mL ampul (IM, IV)   |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
| Phytomenadione (phytonadione, vitamin K1)  | Oral/Inj.: 2 mg/0.2 mL pediatric ampul (IM, IV, PO) (as mixed micelle)<br>Inj.: 10 mg/mL, 1 mL ampul (IM, IV, SC) (as aqueous colloidal solution with benzyl alcohol)<br>10 mg/mL, 1 mL ampul (IM, IV, SC) (as mixed micelle)                       |
| Pilocarpine (as hydrochloride)   | Eye Drops Solution:<br>1%, 10 mL and 15 mL bottle<br>2%, 10 mL and 15 mL bottle   |
| Piperacillin + Tazobactam (as sodium salt)   | Inj.: 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)<br>4 g piperacillin + 500 mg tazobactam per vial (IV infusion)  |
| Pneumococcal Conjugate Vaccine (PCV) Multi-dose vial preparation indicated for the following minimum serotypes: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | Inj.: 10-valent, 2 mL in a 3 mL multidose vial suspension for IM injection<br>13 - valent, 0.5 mL single dose, 0.5 mL pre-filled syringe, 2 mL in multidose vial suspension for IM Injection  |
| Pneumococcal Polyvalent Vaccine  | Inj.: 25 micrograms/0.5 mL (polysaccharide from each capsular type) solution for injection, 0.5 mL pre-filled syringe or single dose vial (IM, SC)<br>25 micrograms/0.5 mL solution for injection, 2.5 mL vial (IM, SC) (multidose)                 |
| Polymyxin B (as sulfate)<br><b>*Reserve Antimicrobial</b>  | Inj.: 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial  |
| Poractant alfa   | Inj.: 80mg/mL sterile suspension (intratracheal/intrabronchial), 1.5 mL and 3 mL vial   |
| Potassium (as citrate)   | Oral: 1080 mg (10 mEq) tablet<br>1620 mg (15 mEq) extended release (ER) tablet  |
| Potassium Chloride   | Oral: 600 mg tablet<br>750 mg durules (as chloride) equiv. to Approximately 10 mEq potassium<br>Inj.: 1 mmol/mL syrup, 30 mL and 60 mL (as chloride)<br>2 mEq/mL, 2 mL and 5 mL ampul (IV infusion)<br>2 mEq/mL, 10 mL and 20 mL vial (IV infusion) |
| Potassium Phosphate  | Inj.: 224 mg monobasic potassium phosphate equiv. to 3 mmol ph  |

| Active Ingredient                                    | Route of Administration<br>Pharmaceutical Forms and Strengths   |
|--|---|
|  | osphorus and 4.4 mEq K/236 mg<br>dibasic potassium phosphate anhydrous per<br>mL in 5 mL vial (IV)  |
| Povidone Iodine                                      | Oral Antiseptic:<br>1%, 60 mL, 120 mL and 240 mL bottle Ointment:<br>10%, 5 g, 15 g and 30 g tube<br>Paint: 10%, 10 mL bottle<br>Solution:<br>10%, 15 mL, 30 mL, 60 mL, 120 mL, 1 L and 1<br>gallon bottle<br>Surgical Skin Cleanser:<br>7.5%, 60 mL, 120 mL, 480 mL, 1 L and 1 gallon bottle |
| Pralidoxime Chloride (1, 2)                          | Inj.: 50 mg/mL, 20 mL vial (IV)   |
| Praziquantel (B)                                     | Oral: 600 mg tablet (available under DOH program)   |
| Prednisolone   | Oral: 15 mg/5 mL syrup, 60 mL (as sodium phosphate)<br>Eye Drops Suspension:<br>0.5% and 1%, 5 mL bottle (as acetate)   |
| Prednisone   | Oral: 5 mg, 10 mg and 20 mg tablet<br>10 mg/5 mL suspension, 60 mL  |
| Primaquine (as diphosphate)                          | Oral: 26.3 mg (15 mg base) tablet   |
| Propofol (1)   | Inj.: 10 mg/mL, 20 mL ampul (IV)<br>10 mg/mL, 50 mL pre-filled syringe (IV)<br>10 mg/mL, 20 mL and 50 mL vial (IV)  |
| Propranolol (as hydrochloride)                       | Oral: 10 mg and 40 mg tablet  |
| Propylthiouracil                                     | Oral: 50 mg tablet  |
| Protamine Sulfate (1, 2)                             | Inj.: 10 mg/mL, 5 mL and 25 mL ampul (IV)   |
| Prothionamide  | Oral: 250 mg film coated tablet   |
| Proxymetacaine (proparacaine)<br>(as hydrochloride)  | Eye Drops Solution:<br>0.5%, 5 mL and 15 mL bottle  |
| Pyrazinamide   | Oral: 500 mg tablet<br>250 mg/5 mL and 500 mg/ 5mL suspension, 120 mL   |
| Pyridostigmine (as bromide)<br>(1, 2)                | Oral: 60 mg tablet  |
| Pyridoxine (vitamin B6) (as<br>hydrochloride) (1, 2) | Oral: 100 mg tablet   |
| Pyrimethamine (B)                                    | Oral: 25 mg and 75 mg tablet  |
| <b>Q</b>   |   |
| Quetiapine (as fumarate)                             | Oral: 25 mg, 100 mg, 200 mg and 300 mg tablet   |
| Quinine  | Oral: 325 mg (300 mg base) tablet (as sulfate)<br>Inj.: 300 mg/mL, 1 mL ampul (IV) (as dihydrochloride)<br>250 mg/mL, 1 mL ampul (IV) (as dihydrochloride)  |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| <b>R</b>  |  |
| Rabeprazole sodium  | Oral: 10 mg and 20 mg tablets  |
| Rabies Immunoglobulin (human)                             | Inj.: 150 IU/mL, 2 mL and 5 mL vial (IM)<br>150 IU/mL, 2mL, 5 mL and 10 mL ampul (IM)  |
| Rabies vaccine, Chick Embryo Cell (purified, inactivated) | Inj.: lyophilized powder, 2.5 IU/mL, 1 dose vial + 1 mL diluent (ID, IM)   |
| Rabies vaccine, Vero Cell (purified)                      | Inj.: lyophilized powder, 2.5 IU/ 0.5 mL, vial + diluent (ID, IM)<br>2.5 IU/mL suspension, 1 mL vial (IM)  |
| Ranitidine (as hydrochloride)                             | Oral: 150 mg and 300 mg tablet<br>75 mg/5 mL syrup, 60 mL and 150 mL<br>Inj.: 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)  |
| Regular, Insulin (recombinant DNA human)                  | Inj.: 100 IU/mL, 3 mL pre-filled syringe (SC, IV/IM)<br>100 IU/mL, 5 mL and 10 mL vial (SC, IV/IM)   |
| Remifentanyl  | Inj.: 1 mg and 2 mg (in vial) lyophilized powder (IV Infusion)   |
| Retinol (vitamin A) (as palmitate) (2)                    | Oral: 10,000 IU, 25,000 IU and 50,000 IU soft gel capsule<br>100,000 IU and 200,000 IU soft gel capsule with nipple (only for DOH program) (B)   |
| Ribavirin   | Oral: 200 mg, 500 mg and 600 mg tablet   |
| Rifabutin   | Oral: 150 mg capsule (for HIV/AIDS patient on concomitant protease inhibitor therapy, in lieu of rifampicin)   |
| Rifampicin  | Oral: 300 mg, 450 mg and 600 mg tablet/capsule (B)<br>200 mg/5 mL suspension, 120 mL   |
| Rifapentine   | Oral: 150 mg film coated tablet  |
| Rifaximin   | Oral: 200 mg tablet  |
| Rilpivirine (as hydrochloride)                            | Oral: 25 mg tablet   |
| Risperidone   | Oral: 1 mg, 2 mg, 3 mg and 4 mg tablet<br>1 mg and 2 mg orodispersible tablet 1 mg/mL oral solution, 100 mL<br>Inj.: 25 mg and 37.5 mg MR powder for suspension, vial + 2 mL diluent in pre-filled syringe (IM)<br>50 mg prolonged-release powder for suspension for injection (IM) with 2 mL diluent (This should not be administered to patients with dementia- related psychoses because of high risk of cardiovascular and infectious-related deaths.) |
| Rituximab (1, 2)  | Inj.: 10 mg/mL, 10 mL and 50 mL vial (IV)  |

| Active Ingredient                                       | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| Rivastigmine (as hydrogen tartrate)                     | Oral: 1.5 mg, 3 mg, and 6 mg capsule   |
| Rocuronium (as bromide) (1)                             | Inj.: 10 mg/mL, 5 mL ampul/vial (IV)   |
| Ropivacaine (as hydrochloride)                          | Inj.: 10 mg/mL, 10 mL ampul (IV)   |
| Rosuvastatin (as calcium salt)                          | Oral: 10 mg and 20 mg tablet   |
| <b>S</b>  |  |
| Sacubitril/Valsartan                                    | Oral: 50 mg, 100 mg and 200 mg tablet <b>(Restricted for patients with symptomatic heart failure with reduced ejection fraction (HF-rEF) and for those who have been on stable doses of angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) but remain symptomatic.)</b>  |
| Salbutamol (as sulfate)                                 | Oral: 2 mg/5 mL syrup, 60 mL<br>Inhalation:<br>Dry Powder Inhaler (DPI):<br>200 micrograms/dose with appropriate accompanying dispenser<br>Metered Dose Inhaler (MDI):<br>100 micrograms/dose x 200 actuations<br>Breath Actuated MDI:<br>100 micrograms/dose x 200 actuations<br>Resp. Soln.:<br>(for nebulization)<br>1 mg/mL, 2.5 mL (unitdose)<br>2 mg/mL, 2.5 mL (unitdose) |
| Salicylic Acid  | Solution:<br>5%, 30 mL and 60 mL bottle  |
| Sambong [Blumea balsamifera (L) DC (Fam. Compositae)] ● | Oral: 250 mg and 500 mg tablet   |
| Selegiline (as hydrochloride)                           | Oral: 5 mg tablet  |
| Selenium Sulfide  | Lotion: 2.5%, 100 mL bottle  |
| Sertraline (as hydrochloride)                           | Oral: 50 mg tablet   |
| Sevelamer carbonate                                     | Oral: 800 mg tablet<br>800 mg powder for suspension  |
| Sevoflurane (1)   | Inhalation:<br>250 mL bottle   |
| Silver Sulfadiazine                                     | Cream: 1%, 15 g and 25 g tube<br>500 g jar (micronized)  |
| Simvastatin (1)   | Oral: 20 mg and 40 mg tablet   |
| Sirolimus (1, 2)  | Oral: 0.5 mg and 1 mg tablet   |

| Active Ingredient   | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---|--|
| Sodium Bicarbonate  | Oral: 325 mg and 650 mg tablet<br>Inj.: 1 mEq/mL, 10 mL vial (pediatric), 20 mL, 50 mL and 100 mL ampul/vial (adult) (IV infusion)   |
| Sodium Calcium Edetate (1, 2)                                   | Inj.: 200 mg/mL, 5 mL ampul (IM)   |
| Sodium Chloride   | Inj.: 2.5 mEq/mL, 20 mL and 50 mL vial   |
| 0.9% Sodium Chloride  | Inj.: 2 mL, 2.5 mL, 5 mL, 10 mL and 20 mL ampul<br>50 mL, 100 mL, 200 mL, 500 mL and 1 L bottle/bag (IV infusion)<br><br>Solution:<br>1 L bottle solution for irrigation<br><br>Composition:<br>Na <sup>+</sup> — 154 mmol/L<br>Cl <sup>-</sup> — 154 mmol/L |
| Sodium Dichloroisocyanurate (to be used for water purification) | Solution:<br>3.5 mg tablet (2 mg free available chlorine)<br>8.68 mg tablet (5 mg free available chlorine)<br>12.5 mg tablet (8 mg free available chlorine)<br>17 mg tablet (10 mg free available chlorine)<br>67 mg tablet (40 mg free available chlorine)  |
| Sodium Hyaluronate  | Ophthalmic Solution:<br>0.1% (1 mg/mL), 5 mL and 15 mL bottle  |
| Sodium Hypochlorite   | Solution: 1.25% available chlorine for water purification  |
| Sodium Iodide <sup>131I</sup> (1, 2)                            | Oral: capsule with radioactivity range of 0.8 to 100 mCi per capsule<br>capsule with radioactivity range of 1.0 to 250 mCi per capsule<br>solution with radioactivity range of 3.5 to 150 mCi per vial   |
| Sodium Nitrite (1, 2)   | Inj.: powder, USP grade  |
| Sodium Nitroprusside (1, 2)                                     | Inj.: 50 mg powder ampul (IV infusion)   |
| Sodium Sulfate  | Oral: powder, USP grade  |
| Sodium Thiosulfate (1, 2)                                       | Inj.: 250 mg/mL, 50 mL ampul (IV)<br>Solution:<br>2.5% and 5%  |
| Sodium Valproate  | Oral: 200 mg / 5 mL syrup, 100 mL bottle   |
| Sodium Valproate + Valproic Acid                                | Oral: 500 mg (333 mg sodium valproate + 145 mg valproic acid) controlled release tablet  |
| Sofosbuvir  | Oral: 400 mg tablet  |
| Sofosbuvir + ledipasvir   | Oral: 400 mg + 90 mg tablet  |
| Sofosbuvir + velpatasvir  | Oral: 400 mg + 100 mg tablet   |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| Somatostatin (1, 2)  | Inj.: 250 microgram and 3 mg ampul/vial (IV, IV infusion)  |
| Soya bean oil + Medium chain triglycerides + Olive oil + Purified fish oil | Inj.: 200 mg/mL (20%) emulsion for IV infusion, 250 mL   |
| Spectinomycin (2)  | Inj.: 2 g vial (IM)  |
| Spironolactone (K-sparer) (2, B)   | Oral: 25 mg, 50 mg and 100 mg tablet   |
| Standard Senna Concentrate   | Oral: 187 mg and 374 mg tablet   |
| Sterile Water for Injection  | Inj.: 2 mL, 5 mL, 10 mL and 20 mL ampul<br>50 mL, 100 mL, 500 mL and 1 L bottle/bag<br>(no preservative) |
| Streptokinase (1, 2)   | Inj.: powder, 1,500,000 IU vial (IV infusion)  |
| Streptomycin (as sulfate)  | Inj.: 1 g vial (IM)  |
| Succimer (dimercapto succinic acid, DMSA) (1, 2)                           | Oral: 100 mg and 200 mg capsule  |
| Sucralfate   | Oral: 1 g tablet   |
| Sugammadex   | Inj: 100 mg/mL solution for injection (IV), 2 mL vial  |
| Sulfacetamide + Prednisolone   | Eye Drops Suspension:<br>10% sulfacetamide + 0.25% prednisolone (as acetate), 5 mL bottle                |
| Sulfamethoxazole + Trimethoprim (see Cotrimoxazole)                        |  |
| Sulfur   | Cream: 2%, 10 g plastic tube<br>Ointment:<br>10%, 15 g and 30 g aluminum collapsible tube                |
| Sumatriptan  | Oral: 50 mg tablet   |
| Suxamethonium (succinylcholine) (as chloride) (1)                          | Inj.: 20 mg/mL, 10 mL vial (IV)  |

## T

|                                   |   |
|-----------------------------------|---|
| Tacrolimus (1, 2)                 | Oral: 1 mg and 5 mg capsule<br>1 mg and 5 mg slow-release capsules  |
| Tafluprost                        | Ophthalmic solution:<br>15 mcg/mL, 0.3 mL bottle single dose ophthalmic solution  |
| Tamoxifen (as citrate) (1, 2)     | Oral: 10 mg and 20 mg tablet  |
| Tamsulosin                        | Oral: 200 micrograms capsule (as hydrochloride)<br>200 mcg orally disintegrating tablet<br>400 mcg prolonged release film coated tablet |
| Tegafur + Uracil (1, 2)           | Oral: 100 mg + 224 mg capsule   |
| Telmisartan                       | Oral: 40 mg and 80 mg tablet  |
| Telmisartan + Hydrochlorothiazide | Oral: 40 mg + 12.5 mg tablet  |

| Active Ingredient                     | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|---------------------------------------|--|
| Tenofovir alafenamide fumarate        | Oral: 25 mg tablet   |
| Tenofovir disoproxil fumarate         | Oral: 300 mg tablet  |
| Tenofovir + Lamivudine + Dolutegravir | Oral: 300 mg + 300 mg + 50 mg (fixed-dose combination) tablet  |
| Terazosin (as hydrochloride)          | Oral: 1 mg, 2 mg and 5 mg tablet   |
| Terbinafine                           | Oral: 250 mg tablet  |
|                                       | Cream: 1%, 3 g, 5 g, 10 g and 15 g tube (as hydrochloride)   |
| Terbutaline (as sulfate)              | Oral: 5 mg tablet<br>1.5 mg/5 mL syrup, 60 mL<br>Inj.: 500 micrograms/mL, 1 mL ampul (IM, IV, SC)<br><br>Inhalation:<br>Resp. Soln.:<br>(for nebulization) 2.5 mg/mL, 2 mL unit dose               |
| Testosterone (as undecanoate) (1)     | Inj.: 250 mg/mL solution for injection, 4 mL   |
| Tetanus Immunoglobulin (human)        | Inj.: 1000 IU/mL, 1.5 mL vial (IM)<br>1500 IU/mL, 1 mL ampul (IM)<br>250 IU/mL, 1 mL, 2 mL and 4 mL ampul (IM)<br>250 IU/mL, 1 mL pre-filled syringe (IM)<br>250 units/mL, 1 mL and 2 mL vial (IM) |
| Tetanus Toxoid                        | Inj.: 0.5 mL ampul (IM)<br>10 mL vial (IM)   |
| Tetracaine                            | Inj.: 20 mg ampul (sterile powder) (spinal) (as hydrochloride)   |
| Tetracycline                          | Oral: 250 mg and 500 mg capsule  |
| Theophylline (anhydrous)              | Oral: 150 mg and 200 mg tablet (B)<br>200 mg MR tablet<br>25 mg/5 mL (26.7 mg/5 mL) syrup, 100 mL  |
| Thiamine (Vitamin B1)                 | Oral: 100 mg and 300 mg tablet (as hydrochloride)<br>Inj.: 100 mg/mL, 1 mL ampul/vial (IV)<br>100 mg/mL, 10 mL vial (as hydrochloride) (IM, IV)  |
| Thiopental Sodium (1, A1)             | Inj.: 500 mg vial (IV)<br>1 g vial + 50 mL diluent (IV)  |
| Timolol (as maleate)                  | Eye Drops Solution:<br>0.5%, 5 mL bottle   |
| Tinzaparin (as sodium) (1, 2)         | Inj.: 10,000 anti-Xa IU/mL, 0.35 mL and 0.45 mL pre-filled syringe (SC)<br>10,000 anti-Xa IU/mL, 2 mL vial (SC)  |
| Tiotropium (as bromide)               | Inhalation:<br>DPI: 18 micrograms/dose with appropriate  |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
|  | accompanying dispenser   |
| Tobramycin   | Eye Drops Solution:<br>0.3%, 5 mL bottle<br>Eye Ointment:<br>0.3%, 3.5 g tube  |
| Tobramycin + Dexamethasone                                       | Eye Drops Suspension:<br>0.3% + 0.1%, 5 mL bottle<br>Eye Ointment:<br>0.3% + 0.1%, 3.5 g tube  |
| Tocilizumab  | Inj.: 80 mg/4 mL (20 mg/mL) Concentrate for Solution for IV Infusion<br>200 mg/10 mL (20 mg/mL) Concentrate for Solution for IV Infusion<br>400 mg/20 mL (20 mg/mL) Concentrate for Solution for IV Infusion |
| Tolvaptan  | Oral: 15 mg tablet   |
| Topiramate   | Oral: 25 mg, 50 mg and 100 mg tablet   |
| Trace Elements   | Inj.: contains Zn, Cu, Mn, Mg, Mb etc., 10 mL ampul (IV nutrition)   |
| Tramadol (as hydrochloride) (1)                                  | Oral: 50 mg capsule<br>50 mg dispersible tablet<br>100 mg, 150 mg and 200 mg MR tablet<br>Inj.: 50 mg/mL, 1 mL and 2 mL ampul (IM, IV, SC)   |
| Tranexamic Acid  | Oral: 250 mg and 500 mg capsule 500 mg tablet<br>Inj.: 100 mg/mL, 2.5 mL and 5 mL ampul (IM, IV)   |
| Trastuzumab (1, 2)   | Inj.: 150 mg lyophilized powder (IV infusion)<br>600 mg/5 mL (120 mg/mL) solution for injection (SC), 5 mL vial  |
| Travoprost   | Ophthalmic Solution:<br>0.004%, 2.5 mL bottle  |
| Triclabendazole  | Oral: 250 mg tablet  |
| Trimetazidine (as hydrochloride)                                 | Oral: 35 mg tablet   |
| Tropicamide  | Eye Drops Solution:<br>0.5%, 5 mL bottle   |
| Tropicamide + phenylephrine hydrochloride                        | Ophthalmic Solution:<br>5 mg + 5 mg/mL (eye drops) fixed dose combination, 10 mL bottle  |
| Tsaang Gubat • [Carmona retusa (Vahl) Masam (Fam. Boraginaceae)] | Oral: 250 mg tablet  |
| Tuberculin, Purified Protein Derivative (PPD)                    | Inj.: 2 TU/0.1 mL solution, 1 mL and 5 mL vial (ID)<br>5 TU/0.1 mL, freeze-dried powder, vial + 2 mL diluent ampul (ID)  |

| Active Ingredient  | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| Typhoid Vaccine  | Oral: live attenuated <i>S. typhi</i> (not less than 109) viable strain, enteric coated tablet(encapsulated)<br>Inj.: Vi-capsular polysaccharide <i>S. typhi</i> 25 micrograms in 0.5 mL pre-filled syringe (IM)   |
| U  |  |
| Ursodeoxycholic Acid   | Oral: 250 mg capsule<br>250 mg and 500 mg tablet   |
| V  |  |
| Valaciclovir (as hydrochloride)                                | Oral: 500 mg tablet  |
| Valganciclovir   | Oral: 450 mg tablet  |
| Valproic Acid  | Oral: 250 mg/5 mL syrup, 120 mL<br>Inj.: 500 mg/ 5mL IV infusion, 5 mL vial  |
| Valsartan  | Oral: 80 mg and 160 mg tablet/film coated tablet   |
| Valsartan + Hydrochlorothiazide                                | Oral: 80 mg valsartan + 12.5 mg hydrochlorothiazide tablet   |
| Vancomycin (as hydrochloride)<br><b>*Reserve Antimicrobial</b> | Inj.: 500 mg and 1 g vial (IV)   |
| Varenicline  | Oral: 0.5 mg and 1 mg tablet   |
| Varicella Zoster Immunoglobulin (VZIG)                         | Inj.: 125 units/1.25 mL vial (IM)  |
| Vasopressin  | Inj.: 20 IU/mL (IM, IV)  |
| Vecuronium (as bromide) (1, 2)                                 | Inj.: freeze-dried powder, 4 mg/mL ampul + 1 mL solvent (IV)   |
| Verapamil (as hydrochloride)                                   | Oral: 80 mg tablet (B)<br>240 mg MR tablet (for maintenance therapy)<br>Inj.: 2.5 mg/mL, 2 mL ampul (IV) (1, 2)  |
| Vinblastine (as sulfate) (1, 2)                                | Inj.: powder, 10 mg vial for reconstitution (IV)<br>1 mg/mL, 10 mL vial (IV)   |
| Vincristine (as sulfate) (1, 2)                                | Inj.: 1 mg/mL, 1 mL and 2 mL vial (IV)   |
| Vitamin A (see Retinol)  |  |
| Vitamin B1 B6 B12  | Oral: 100 mg B1 + 5 mg B6 + 50 microgram B12 per tablet/capsule<br>10 mg B1 + 5 mg B6 + 5 micrograms B12 per 0.6 mL drops, 15 mL<br>Inj.: 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)<br>100 mg B1 + 100 mg B6 + 1 mg B12 per mL, 10 mL vial (IV) |
| Vitamin B6 (see Pyridoxine)                                    |  |
| Vitamin C (see Ascorbic Acid)                                  |  |

| Active Ingredient                            | Route of Administration<br>Pharmaceutical Forms and Strengths  |
|--|--|
| Vitamin Intravenous, Fat-Soluble             | Inj.: contains vitamins A, D, E and K, 10 mL ampul (IV)  |
| Vitamin Intravenous, Water-Soluble           |  |
| Vitamin K1 (see Phytomenadione)              |  |
| Voriconazole (Inj. - *Reserve Antimicrobial) | Oral: 200 mg film-coated tablet<br>Inj.: 200mg lyophilized powder for solution for IV infusion, 30mL Vial  |
| <b>W</b>                                     |  |
| Warfarin (as sodium salt) (1, 2)             | Oral: 1 mg, 2.5 mg and 5 mg tablet   |
| <b>Y</b>                                     |  |
| Yellow Fever Vaccine                         | Inj.: 1000 DL 50 mouse min (attenuated) vial + 0.5 mL solvent syringe (IM, SC) (For Bureau of Quarantine Use Only)   |
| <b>Z</b>                                     |  |
| Zidovudine                                   | Oral: 100 mg capsule<br>300mg tablet<br>50mg/5mL suspension, 240mL per bottle  |
| Zidovudine + Lamivudine                      | Oral: 60 mg + 30 mg dispersible tablet   |
| Zinc   | Oral: chewable tablet, (equiv. to 10 mg elemental zinc) (as gluconate)<br>tablet, (equiv. to 30 mg elemental zinc) (as gluconate trihydrate)<br>88mg dispersible tablet (equivalent to 20mg zinc) (as sulfate)<br>solution, (equiv. to 10 mg elemental zinc/mL) drops, 15 mL, (as sulfate monohydrate)<br>solution, (equiv. to 20 mg elemental zinc/5 mL)<br>syrup, 60 mL (as sulfate monohydrate)<br>70 mg/5 mL syrup (equivalent to 10 mg elemental zinc), 60 mL and 120 mL (as gluconate) |
| Zoledronic Acid                              | Inj.: 4mg/5mL concentrated solution for IV Infusion  |
| Zolmitriptan                                 | Oral: 2.5 mg tablet  |
| Zolpidem (A1)                                | Oral: ⊗10 mg tablet  |

## FREQUENTLY ASKED QUESTIONS (FAQS)

1. What is the Philippine National Formulary(PNF)?
  - It contains the list of essential medicines that can be procured by the government. It also serves as the basis for Philhealth reimbursement for both public and private health facilities.
2. Who can apply medicines for inclusion in thePNF?
  - Only the following proponents can apply in thePNF:
    - A. Pharmacy and Therapeutics Committee (PTC) of both public and private hospitals
    - B. Professional medical societies recognized by the Philippine Medical Association (PMA)
    - C. Patient groups
    - D. National Health Programs (DOH Offices,Philhealth)
    - E. Formulary Executive Council
    - F. National Antibiotic Guidelines Committee
3. How to apply for inclusion of medicines in the PNF?
  - Applications for inclusion shall only be accepted within the month of January of each year.
  - The proponent shall completely accomplish the PNF form for inclusion, which shall be signed by the:
    - A. PTC Chair for hospitals
    - B. President for professional medical societies and patient organization
    - C. Head of Office for National Health Programs
  - The form may be downloaded from the Pharmaceutical Division website, [www.pharmadiv.doh.gov.ph](http://www.pharmadiv.doh.gov.ph)
  - Application may also be done online through: <http://www.pnf.doh.gov.ph>
  - The PNF secretariat shall check the completeness of submission before it will be presented to the Formulary Executive Council. Incomplete submissions will not be processed and will be returned to the proponent.
4. How to procure non-PNF medicines that are urgently needed?
  - This can be done through application for exemption from Executive Order No. 49 s. 1993 (*Directing the Mandatory Use of the Philippine National Drug Formulary (PNDF) Volume I as the Basis for Procurement of Drug Products by the Government*). The health facility shall completely accomplish the PNF form for exemption, which shall be signed by the:
    - A. PTC Chair for hospitals
    - B. Head of Office for National Health Programs
  - The form may be downloaded from the Pharmaceutical Division website, [www.pharmadiv.doh.gov.ph](http://www.pharmadiv.doh.gov.ph)
  - The PNF secretariat shall check the completeness of submission before it will be presented to the Formulary Executive Council. Incomplete submissions will not be processed and will be returned to the proponent.
5. If an exemption is granted to a certain medicine, will this be applicable to all health facilities?
  - Only the requesting health facility shall be allowed to procure the exempted medicine. A certificate of exemption with a validity of one (1) year shall be issued to the proponent.
6. How do I get updates on the PNF?
  - Please visit the website of the Pharmaceutical Division, [www.pharmadiv.doh.gov.ph](http://www.pharmadiv.doh.gov.ph), for the updated list of PNF medicines.
  - You may also directly contact the PNF secretariat and look for Ms. Joyce Anne Ceria-Pereña or Ms. Johanna Mallari through the following:
    - A. Email address: [pnf.doh@gmail.com](mailto:pnf.doh@gmail.com) / [pndfs.secretariat@gmail.com](mailto:pndfs.secretariat@gmail.com)
    - B. Telephone number: 875-7734 ext.253

## RESERVE ANTIMICROBIALS

### RESERVE ANTIBACTERIAL

| Medicine   | Dosage Forms/Strengths                                      |
|------------|---|
| Aztreonam  | 1 g Powder for injection                                    |
| Cefepime   | 500 mg (as Hydrochloride) Vial (IM, IV)                     |
|            | 1 g (as Hydrochloride) Vial (IM, IV)                        |
|            | 2 g (as Hydrochloride) Vial (IM, IV)                        |
| Colistin   | 2,000,000 IU Lyophilized powder for injection (IV infusion) |
| Ertapenem  | 1 g (as Sodium) Powder Vial (IM,IV)                         |
| Linezolid  | 600 mg Tablet / Film-coated tablet                          |
|            | 2 mg/mL (600 mg/300 mL) Solution for IV infusion (IV)       |
| Meropenem  | 500 mg (as Trihydrate) Powder Vial (IV)                     |
|            | 1 g (as Trihydrate) Powder Vial (IV)                        |
| Vancomycin | 500 mg (as Hydrochloride) Vial (IV)                         |
|            | 1 g (as Hydrochloride) Vial (IV)                            |

### RESERVE ANTIFUNGALS

| Medicine       | Dosage Forms/Strengths  |
|----------------|---|
| Amphotericin B | 50 mg (as Cholesteryl complex, colloidal dispersion) Vial (Lipid complex) |
|                | 100 mg Vial (Lipid complex)   |
|                | 50 mg Lyophilized powder Vial (Non-lipid complex)                         |
| Micafungin     | 50 mg Lyophilized powder for infusion (IV)                                |
| Voriconazole   | 200 mg Film coated tablet   |
|                | 200 mg Lyophilized powder for solution for IV infusion, 30 mL Vial        |

